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Summary
Tamoxifen is a potent anti cancer agent and has long been the standard for adjuvant 
endocrine therapy in breast cancer in the United Kingdom. Despite this success, 
resistance to Tamoxifen is a significant clinical problem; almost all patients with 
metastatic disease experience progression and up to 2 0 % of early breast cancer 
patients relapse whilst on adjuvant treatment. The primary mechanism of action of 
Tamoxifen is via competitive inhibition of oestrogen binding to oestrogen receptors. 
The subsequent reduction in expression of oestrogen related genes such as growth 
factors and angiogenic factors results in reduced cell proliferation, enhanced apoptosis 
and reduced cell growth. However as the complexity of oestrogen receptor function is 
increasingly revealed, particularly in terms of its mechanism of action and interactions 
with other signalling pathways, our understanding of Tamoxifen activity and the 
development of resistance against it has also expanded.
Tamoxifen resistance may be either novo ” (present prior to Tamoxifen treatment) 
or “acquired” during the course of treatment. Identifying the biological mechanisms 
behind Tamoxifen resistance is important paiticulaily as increasing clinical trials 
evidence implies superiority of aromatase inhibitors over Tamoxifen. It is not 
currently clear whether this superiority is the case for all ER positive patients, or 
whether there is a particular group of patients resistant to Tamoxifen whose tumours 
may be sensitive to aromatase inhibitors.
The HER family of tyrosine kinase receptors (HERl-4) initiate a complex signal 
transduction cascade modulating cell proliferation, survival, adhesion, migration and 
differentiation. We have postulated that cross talk between the HER family and the 
ER may underlie development of Tamoxifen resistance in breast cancer. We have
14
used tissue microarray technology and immunohistochemistry in analysis of a 
retrospective database of 402 ER positive. Tamoxifen treated patients to test the 
hypothesis that overexpression of HER family members 1-3 is associated with 
phosphorylation of the ER and with clinical relapse on Tamoxifen (‘Tamoxifen 
resistance’).
We have demonstrated that H ERl-3 (but not HER4) and PR status can identify time- 
dependent de novo Tamoxifen resistance, with risk declining markedly after 3 years 
o f tamoxifen treatment. We also demonstrate for the first time in vivo expression of 
phosphorylated ERa at the cell membrane of breast cancer cells and have 
demonstrated a correlation between H ER l-3 status and membranous phosphorylated 
ER. This supports recent reports of an interaction between membrane-bound ERa and 
the HER family and its pathways and provides further evidence for the non-classical 
actions of the ERa at the membrane. We confirm previous reports that phosphorylated 
ERa in the nucleus is associated with higher ERa expression and a more 
differentiated phenotype suggesting that it acts as a marker of an intact, functional, 
ERa signalling pathway.
Data presented here demonstrates the significant role played by H ER l-3 in promoting 
Tamoxifen resistance in hormone responsive breast cancers. It also emphasises the 
different role of HER4 in this context. This work is particularly clinically relevant 
with recent trials suggesting that the apparent superiority of aromatase inhibitors over 
Tamoxifen may be linked to the expression of specific tumour markers. In fact oui" 
results parallel those from the AT AC and lES trials which suggest that, whilst PR 
negative patients derive greater benefit from initial aromatase inhibitor treatment, PR 
status has no impact on response when given as delayed treatment to those who were 
disease free on Tamoxifen after 3 years.
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Taken together, these data strongly supports the conclusion that the predictive value 
of PR, and possibly H ERl-3, expression is time dependent and identifies patients at 
high risk of de novo Tamoxifen resistance. The ability to select, at diagnosis, patients 
at high risk of early relapse on Tamoxifen could provide the opportunity to tailor their 
adjuvant therapy on an individual basis, either in terms of an aromatase inhibitor or by 
supplying them with a HER family inhibitor such as 1res sa or Herceptin to be used in 
conjunction with their endocrine treatment.
There is some evidence that, in contrast to genomic activity, non-genomic ERa 
activity can be stimulated by SERMS such as Tamoxifen. Therefore Tamoxifen may 
be incapable of breaking (or even may stimulate) any cycle linking non-genomic and 
genomic ERa with the growth factor pathways. From our results, we speculate that 
membrane bound ERa, in conjunction with the HER family, may be responsible for 
initiating tumour cell proliferation even in the presence of Tamoxifen resulting in de 
novo Tamoxifen resistance. These results have implications for establishing ERa 
status, particularly in the clinical diagnostic setting, as more detailed analysis in terms 
of location and function of the receptor may become the norm for diagnostic testing in 
the future.
Further research is required to determine the mechanisms relating to Tamoxifen 
resistance particularly in regard to the nature of the interactions at the membrane 
between the ER and HER family. Testing these hypotheses in the context of the 
redesigned TEAM trial will provide a valuable insight into the most appropriate future 
therapeutic options for differing sets of breast cancer patients.
16
Chapter 1: Introduction 
1.1 Breast cancer
Breast cancer is the most common female malignancy with more than 40,000 cases 
diagnosed in the UK in 2000. The lifetime risk of developing breast cancer is 1 in 9 
and its incidence is on the increase (www.show.scot.nhs.uk/isd/). Survival rates 
however are improving year on year from a 5 year suivival rate of 52% in the 1970s 
to 80% during the years 1998-2001 (www.statistics.gov.uk/1.
Breast cancer rarely occurs in women under the age of 25 years. Thereafter, the 
incidence increases steadily until the menopause, where the rate of increase slows. 5- 
1 0 % of cases have a known familial predisposition but for the majority aetiology is 
not always clear. Exposure to increased endogenous (early menarche and late 
menopause) or exogenous hormones has been implicated as have environmental 
factors such as, diet/obesity, alcohol and physical activity (Muti, 2004).
1.2 Endocrine Therapy
Endocrine systemic therapy is an effective and minimally toxic method of treating 
homione responsive breast cancers. Indeed endocrine manipulation has been used in 
varying forms since the discovery of the beneficial effects of oophorectomy on young 
women with locally advanced breast cancer (Beatson AT, 1896). Now cancers 
expressing oestrogen receptors aie treated with some form of endocrine therapy to 
abolish the proliferative effect of oestrogen on these tumours. This may be achieved 
by depleting the environment of oestrogen with either aromatase inhibitors or the 
lutenising-hormone-releasing agonist goserelin. Alternatively, treatment that involves
17
competition with oestrogens for binding to the ERa can be used, such as the ‘selective 
oestrogen receptor modulator’ Tamoxifen.
1.2.1 Tamoxifen
Tamoxifen was originally developed as an oral contraceptive, but its potential anti- 
oestrogenic properties were subsequently recognised (Haiper and Walpole, 1966) and 
was introduced as a endocrine agent for the treatment of breast cancer. Initially 
hormone treatment was given to all patients but trial evidence confirmed 
responsiveness in the oestrogen receptor positive patients only (Early Breast Cancer 
Trialists' Collaborative Group, 1998; Stewart, 1992). Tamoxifen subsequently became 
the first line agent in endocrine responsive breast cancer.
The primary mechanism of action of Tamoxifen is via competitive inhibition of 
oestrogen binding to oestrogen receptors. The subsequent reduction in expression of 
oestrogen related genes such as growth factors and angiogenic factors results in 
reduced cell proliferation, enhanced apoptosis and reduced cell growth (Osborne,
1998). However it is not a pure antagonist, and in fact exerts both agonist and 
antagonist effects. Generally it is an agonist in bone and endometrium (Kedar et al., 
1994; Love et al., 1992), whereas it is used for its antagonist effect on genes important 
for cell proliferation or suivival in the breast.
Tamoxifen is a potent anticancer agent and is well established in clinical practice for 
use in ERa positive breast cancer. The Scottish Cancer Trials Breast Group results 
demonstrated tamoxifen, taken for a median duration of 60 months, significantly 
prolonged disease-free survival overall (P = .0001), in both premenopausal (n=214) - 
and postmenopausal (n=533) node negative patients. Analysis of a large number of 
randomised trials (Early Breast Cancer Trialists' Collaborative Group, 1998; Early
18
adjuvant treatment eventually relapsing (Osborne, 1998). This is despite the fact that 
most cases retain the nuclear steroid receptors (Clarke et a l, 2001b). Tamoxifen 
resistance may be either ‘We novo” (present prior to Tamoxifen treatment) or 
“acquired” during the course of treatment. De novo resistance may partially be 
explained by Tamoxifen being used to treat ERa negative tumours or by inadequate or 
inaccurate measurement of the ERa status. However despite this it appears that a 
proportion of ERa positive tumours are intrinsically hormone-independent (McGuire, 
1980).
Despite many years of use, there is still no adequate explanation as to why some 
potentially sensitive tumours become resistant to Tamoxifen. However as the
19
'1
Breast Cancer Trialists' Collaborative Group, 2005) demonstrated a 50% proportional £
reduction in the recurrence rate and a 28% proportional mortality reduction for ERa
.1positive patients taking adjuvant Tamoxifen for 5 years. These overviews
.demonstrated a long term and increasing benefit of Tamoxifen with survival benefits
'Imaximised at 5 years of treatment.
As well as remaining the standard ac^uvant therapy for women with ERa positive
tumours following surgery. Tamoxifen can also achieve tumour regression in many 4j
patients with locally advanced or metastatic disease. It is generally well tolerated and
■I
responses are longer compared to cytotoxic chemotherapy (Dowsett, 2001).
"'4
Side effects of Tamoxifen include menopausal symptoms such as hot flushes and it 
carries an increased risk of thromboembolic disease. Its partial agonist effects include 
uterine proliferation (with an associated increased risk of uterine malignancy) as well 
protective oestrogen like effects on bone metabolism resulting in an increase and 
stabilisation of bone density. Despite its proven benefits however, resistance often 
develops to Tamoxifen, with almost all patients with metastatic disease, and some on
,4
I
complexity of oestrogen receptor function is increasingly revealed, particularly in 
terms of its mechanism of action and interactions with other signalling pathways, our 
understanding of Tamoxifen activity and the development of resistance has also 
expanded. Identifying the biological mechanisms behind Tamoxifen resistance is 
important, particularly as increasing clinical trials evidence implies superiority of 
aromatase inhibitors over Tamoxifen (Dowsett, 2003).
1.2.2 Aromatase Inhibitors
Aromatase is a cytochrome P450-dependent enzyme, which acts at the last step in the 
synthesis of oestrogen by catalyzing the conversion of androgens to estrogens. 
Aromatase inhibitors work by preventing conversion of androstenedione to oestrone 
and oestrodiol in peripheral tissues (fat, muscle etc) and locally within established 
breast tumours (Reviewed in (Caipenter and Miller, 2005). By inhibiting aromatase, 
the levels of plasma oestrogens are reduced by over 97% in postmenopausal women 
(Brodie andNjar, 1996).
Earlier aromatase inhibitors also affected adrenal corticosteroid function but current 
third generational potent selective inhibitors do not have these potentially toxic side 
effects. They may be steroidal (Exemestane) or non-steroidal (Arimidex, Letrozole). 
Steroidal AIs are analogues of androstenedione and are noncompetative, irreversible 
inhibitors of the aromatase enzyme. The non-steroidal inhibitors act by binding 
reversibly to the enzyme complex. Both classes have been shown to reduce 
circulating oestrogen to 1% to 10% of pretreatment levels (Buzdar et a l, 1997). Initial 
evidence with regard to the efficacy of these newest aromatase inhibitors has come 
from the neoadjuvant (Ellis et a l, 2001) and metastatic settings (Mouridsen et al, 
2001; Nabholtz et a l, 2003) and these drugs are commonly used as the first line
20
treatment in these cases. In the adjuvant setting whilst emerging data on the efficacy 
of aromatase inhibitors does not yet identify a group of patients for whom additional 
benefit is derived in terms of overall survival, the AT AC (Arimidex, Tamoxifen, 
alone or in combination), IBS (Intergroup Exemestane Study) and BIG-98 studies all 
demonstrate a clear benefit in terms of disease free survival (Coombes et al., 2004b; 
Howell and on behalf of AT AC trialists' Group, 2004; Coates et a l, 2007). It is not 
currently clear whether this superiority is the case for all ERa positive patients, or 
whether, as is widely predicted, there is a particular group of patients resistant to 
Tamoxifen whose tumours may be sensitive to aromatase inhibitors. There is 
however, growing evidence that specific tumour markers may be used to identify 
tumours which exhibit resistance to Tamoxifen and/or demonstrate enhanced 
responsiveness to aromatase inhibitors (Schiff et a l, 2004; Ross and Fletcher, 1998; 
Dowsett, 2003). These markers include both conventional markers of endocrine 
responsiveness (ERa and PR) and receptor tyrosine kinases such as the human 
epithelial growth factor (HER) family of receptors.
It has been suggested that cross-talk between the oestrogen receptor and HER family 
may underlie Tamoxifen resistance (Schiff et a l, 2004) and thus may also go some 
way towards explaining the superior clinical results demonstrated with aromatase 
inhibitors.
21
1.3 Oestrogen receptor
In order to explore the potential mechanisms underlying Tamoxifen resistance, it is 
necessary to first attempt to understand the complex behaviour of the oestrogen 
receptor. Oestrogen action is mediated through the oestrogen receptors ERa and ERP; 
both members of the nuclear hormone receptor superfamily. Although more 
information about ERP is now available, most of our knowledge about the role 
oestrogen plays in breast cancer is with regard to its’ actions via ERa.
ERa is a 65kDa nuclear transcription factor receptor expressed in 46-77% of breast 
cancers (Robertson, 1996). The conventional pathway for ERa action is well 
described (Figure 1). The ERa exists as a monomer bound by heat shock proteins. 
Subsequent ligand binding causes dissociation of the heat shock proteins and 
alteration of receptor conformation. In this classical pathway the activated receptors 
then homodimerize, and in a complex with coregulatory molecules bind to oestrogen 
responsive elements (ERE) in the promoter region of target genes, to alter 
transcription (Klein-Hitpass et al., 1988; Kumar and Chambon, 1988). The targets of 
proliferative oestrogen/ERa action include genes such as fas, jiin-B and myc (Weisz 
and Bresciani, 1993), cell cycle-controlling gene products such as cyclin D1 
(Musgrove et a l, 1993), cyclin-dependent kinase inhibitors (Planas-Silva and 
Weinberg, 1997) and growth factors and their pathways (Migliaccio et a l, 1996; 
Dickson and Lippman, 1995).
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Figure 1
Ihe ER is composed o f an N-terminal domain (NTD), a central DNA binding domain 
(DBD) and a C-terminal ligand-binding domain (LED). Oestrogen binding to the ER 
causes dissociation o f the heat shock proteins (HSP). The activated receptor 
subsequently homodimerize and form a complex with co-activators (A) and co­
repressors (R), which binds to oestrogen response elements (ERE) in the promoter 
region o f  target genes.
Like other nuclear steroid receptors, the ERa is comprised o f an N-terminal domain 
(NTD), a central DNA binding domain (DBD) and a C-terminal ligand-binding 
domain (LBD). The DBD mediates ERE recognition. The LBD in region E contains 
an oestrogen-inducible transcription-activating function called AF-2 (Kumar et al., 
1987; Tzukerman et al., 1994). In addition there is a constitutively active
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transcription-activating function AF-1 which is located in the NTD region of the 
receptor (Tora et a l, 1989). AFl and AF2 can function independently or 
synergistically to activate transcription and promote signalling depending on the cell 
and promotor context (Kumar et a l, 1987; Shang and Brown, 2002).
ER activation and its’ subsequent cellulai* actions are in fact more complex than 
originally thought and deviate from the original concept of the classical nuclear 
receptor at more than one level. A background to this will now be outlined, and 
discussed further when considering the implications of this in the development of 
Tamoxifen resistance.
1.3.1 Receptor phosphorylation
Modification of proteins through phosphorylation is a key mechanism by which the 
activity of transcription factors can be regulated (Shao and Lazar, 1999). The ER has 
the potential to be regulated via phosphorylation at all of its domains which results in 
post-translational modifications. Phosphorylation at serines 104 /106, serines 118 and 
167, serine 236 and on tyrosine 537 has been demonstrated using deletional or point 
mutation analysis (Ali et a l, 1993; Castoria et a l, 1993; Le Goff et a l, 1994; Chen et 
a l, 1999).
The AF-1 region is phosphoiylated by components of growth factor pathways (Figure 
2) such as MARK kinases (Kato et a l, 1995) and Akt/Protein Kinase B (Campbell et 
a l, 2001) or by cyclin dependent kinases (Chen et al, 2000; Rogatsky et a l, 1999) to 
promote co-activator recruitment and transactivation. The DBD can be 
phosphorylated by PKA (Chen et a l, 1999) to inhibit transcriptional activity via 
decreasing DNA binding and regulation of dimérisation. In addition the AF2 region
24
can be phosphorylated by Src kinases on tyrosine 537 (Arnold et al., 1997) to enhance 
dimerization, ligand binding and co-regulator recruitment.
POST TRANSLATIONAL MODIFICATION: 
PHOSPORYLATION
CDK2
0 0
MAPK
S104/106 |S118 I S167
Src KINASES
AFl NTD DBD LBD AF2
TRANSACTIVATION DIMERIZATION E SENSITIVITY
Figure 2
Ihe A F l region can be phosphorylated by MAPK kinases, Akt or cyclin dependent 
kinases. The DBD has been shown to be phosphorylated by PKA and the AF2 region 
by Src kinases.
1.3.2 Ligand independent action
The function o f the AF-1 region, which controls ligand-independent activation, seems 
to depend on various factors. AF-1 action appears to be more apparent in various cell 
types (Berry et al., 1990; Webb et al., 2000), in the presence o f high levels of AF-1 
coactivators (Webb et al., 1998), or following activation o f components o f growth
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factor pathways such as MAPK, INK kinase (Font and Brown, 2000; Kato et a l, 
1995) (Feng et a l, 2001) or AKT (Campbell et a l, 2001) activation. In addition 
reports have suggested that cells with high levels of ER expression are able to self- 
generate ligand independent AF-1 transactivation and growth (Fowler et a l, 2004).
1.3.3 Non-genomic action
There is increasing evidence for the non-genomic actions of ER, particularly as an 
explanation for the more rapid (seconds to minutes) signalling that can be produced 
by oestrogen stimulation (Simoncini et a l, 2000; Kousteni et a l, 2001; Castoria et a l,
1999). Under these circumstances the ER is able mediate its rapid actions via direct 
association with signal transduction components without any transcriptional activity 
taking place (Losel et a l, 2003). Some of these non-genomic actions appear to be 
taking place outside the nucleus, either in the cytoplasm or at the membrane. 
Oestrogens appear to be able to mediate some actions through a putative membrane 
associated oestrogen receptor (Watson and Gametchu, 1999; Simoncini et a l, 2000; 
Pappas et a l, 1995). In the late 1970s Pietras & Szego (Pietras and Szego, 1977) 
reported the presence of high affinity binding sites for oestrogen associated with the 
plasma membranes of the MCF7 human breast cell line. This observation was largely 
ignored until recently, when evidence for non-genomic actions of ERa increased. 
Pappas et al co-incub ate d rat pituitary cells with an antibody specific to intracellular 
ER and a fluorescent ER-BSA conjugate. They demonstiated that these labels 
colocalize on cells suggesting that mERa may be structurally similar to intracellular 
ERa. In addition using confocal microscopic methods, translocation of full length 
ERa into the membrane has been demonstrated in response to oestrogen (Song et al,
2002) and transfection of ERa negative cells with ERa resulted in 5% of ER locating
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to the membrane with the remainder mostly in the nucleus (Razandi et a l, 1999). 
Recent work has suggested that these membrane receptors may be particularly 
important in the role oestrogen plays in ‘survival or anti-apoptotic mechanisms 
(Razandi et a l, 2000). Oestrogen stimulation of membrane ERa has been shown to 
result in G protein activation, which results in rapid stimulation of protein kinase C, 
protein kinase A, MAPK and PI3K (Kelly and Levin, 2001; Marquez and Pietias, 
2001). There is also evidence that this membrane receptor may directly signal via 
activation/cross talk with the membrane growth factor EGFR (Razandi et a l, 2000). 
Note that this also provides a mechanism for a positive feedback loop as downstream 
growth factor pathway members such as MAPK and Akt may then phosphorylate the 
ERa as discussed previously.
1.3.4 Co-regulators
ER-mediated gene transcription is regulated at yet another level depending on co- 
regulator availability and function. The receptor interacts with corepressors or 
CO activators that inhibit or enhance its activity on target genes respectively. In the 
inactivated state, the ERa is bound to corepressor complexes. On oestrogen binding, 
the conformational change in AF2 facilitates an interaction with co-activators (Ali and 
Coombes, 2002). Three related co-activators, known collectively as the p i60 co­
activators, stimulate ERa activity following ligand stimulation, via interaction with 
AF-2 (reviewed (Leo and Chen, 2000; McKenna et a l, 1999)). These 3 proteins are 
known as nuclear receptor co-activators NCOAl (also known as SRCl), NCOA2 
(also known as TIF2 or GRIPl) and NCOA3 (also known as P/CIP, ACTR, ATB-1, 
RAC3 orTRAM l).
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1.3.5 Non-classicaï response elements
As well as regulating transcription through classical EREs in the promotor regions of 
target genes, the ER also interacts with a growing number of non classical response 
sites (Savilie et a l, 2000; Weatherman and Scanlan, 2001). These sites do not 
necessarily require DNA-protein interactions between the receptor and promotor 
element, but instead regulate transcription through protein-protein interactions 
between the receptor and other transcription factors such as the fos jun complex (AP- 
1) and Sp-1.
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1.4 Mechanism of action of Tamoxifen and potential 
mechanisms for resistance.
Tamoxifen is not a pure antagonist, and in fact exerts both agonist and antagonist 
effects. Generally it is an agonist in bone and endometrium (Kedar et al., 1994; Love 
et a l, 1992), whereas it is used for its antagonist effect on genes important for cell 
proliferation or survival in the breast.
The antagonist effect of Tamoxifen arises from inhibition of the AF-2 transcription- 
activating function (despite allowing release from heat shock proteins and ERE 
binding) (Figure 3) (Parker, 1996). However unlike steroidal anti-oestrogens such as 
ICI 182,780, (Wakeling et a l, 1991) it does not appear to antagonise the AF-1 
function (McDonnell et al., 1995). Tamoxifen therefore allows weak AF-1 activity 
although in most cases this is insufficient to increase gene transcription (Berry et a l, 
1990), However, in circumstances where the AF-1 region can become activated, this 
activity becomes more significant. This has been thought to explain the mechanism of 
action behind Tamoxifens’ tissue specific partial agonist effects. The ERa activity in 
breast epithelium is due mainly to AF-2 therefore Tamoxifen acts largely as an 
antagonist, whereas in the uterus, the role of AF-1 is more significant, explaining its 
agonist effects there.
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Figure 3
Tamoxifen (TAM) antagonises AF2 transcription activating function but not AF-1 
function.
Several mechanisms have been proposed to explain Tamoxifen resistance (Osborne,
1998);
1.4.1 Loss of ERa
Loss of ERa expression, particularly in metastasis, has been proposed as a mechanism 
for the development of resistance to hormonal therapy. Most ERa positive breast 
cancers will also contain populations of ERa negative cells. Under the selective 
pressure of anti-oestrogen treatment, the ERa negative cells may come to predominate 
so accounting for an apparent switch in their tumour receptor status (Graham et al., 
1992). However there is also convincing evidence that ERa expression is a stable
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phenotype (Robertson, 1996). We know that at least 2/3rds of tumours that become 
resistant to tamoxifen continue to express ERa (Encamacion et a l, 1993). Tamoxifen 
resistant cell lines frequently demonstrate sustained ERa content and remain 
responsive to pure anti-oestrogen therapy (Brunner et al, 1993). We also know that 
tumours that have become resistant to Tamoxifen as an initial endocrine therapy will 
often go on to respond to a 2""* line anti-hormonal treatment such as megace, an 
aromatase inhibitor or oophorectomy (Murray and Pitt, 1982; Robertson et a l, 1989; 
Sawka et a l, 1986), indicating the continued presence of a functional ERa.
1.4.2 Variant/mutant ERa
Mutation of the ER gene could affect function or response to Tamoxifen. There is a 
naturally occurring ER mutant that recognises Tamoxifen as an agonist only (Fuqua,
1994). However the effect that these mutants have on clinical resistance in vivo is yet 
to be determined (Hopp and Fuqua, 1998).
1.4.3 Presence/altered expression of ERp
In 1996 a second ER was identified (Mosselman et a l, 1996) with subsequent 
identification of various isoforms such as ER(31(wildtype), ER(32 (identical to |3cx), 
ER|33, ER(34, ER(35, and ERA5), (Lewandowski et a l, 2002; Ogawa et a l, 1998; 
Tong et a l, 2002). ERp is highly homologous to the ERa and has been shown to bind 
estrogens with an affinity similar to that of ERx, and activates expression of reporter 
genes containing oestrogen response elements in an oestrogen-dependent manner. 
When a gene does not require activation of the ER’s AF-1 function, ERa and ERp 
appear equivalent at regulation of tianscription (Cowley and Parker, 1999). However, 
in addition to acting as a homodimer, ERB also heterodimerizes with ERa (Pace et a l.
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1997). Evidence suggests that the expression of functional ERa/p heterodimers, may 
result in unique patterns of gene regulation, many of which are distinct from the genes 
regulated by the ER homo dimers (Monroe et al., 2005).
It has been suggested that an altered ratio of ERa: ERp may occur during 
carcinogenesis (Leygue et al., 1998) with the ERa proportion progressively increasing 
as the cells acquire a more aggressive phenotype. This alteration in ERa: ERp ratio 
may also play a role in Tamoxifen resistance (Speirs et al., 1999; Salvatori et al.,
2003). Recent in vitro evidence has confirmed that high levels of ER-beta predicted 
for improved disease-free and overall survival in patients treated with adjuvant 
tamoxifen therapy (Hopp et al., 2004b). However more studies are required to 
examine the role of various isoforms with a report from small numbers of patients 
suggesting ERPcx in primaiy lesions correlated with a poor response to tamoxifen 
(Saji et al., 2002).
1.4.4 Tamoxifen agonist stimulation of growth
In some patients it appears that Tamoxifen therapy can stimulate tumour growth. This 
is illustrated by the clinical response sometimes shown after Tamoxifen is stopped 
because of progression, and explains a lack of response to oophorectomy in 
premenopausal women who remain on Tamoxifen (Wiebe et al., 1993). In addition 
clinical trials have suggested that longer treatment with adjuvant Tamoxifen is no 
better, and may possibly be worse, than the standard 5 year treatment (Fisher et al., 
2001; Early Breast Cancer Trialists' Collaborative Group, 1998).
MCF-7 breast cancer cell line engrafts can be selected in vivo to become stimulated 
by tamoxifen (Osborne et al., 1987). More recently an explanation for this has been 
proposed involving a disturbance between ERa and its’ coactivators and corepressors
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(Smith et al., 1997; Osbome et al., 2003) (Figure 4). It is suggested (Takimoto et al.,
1999) that Tamoxifen antagonism may not be a passive competitive process but may 
involve active recruitment of corepressor or coactivator proteins to produce mixed 
responses. These studies suggest that an increasing ratio of antagonist specific 
coactivators to corepressors may lead to inappropriate agonist activity so producing 
the hormonal resistant state.
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Figure 4
An increasing ratio o f coactivators (A) to core pres sors (R) may lead to inappropriate 
Tamoxifen agonist activity.
One particular coactivator AIBl, which may be activated by growth receptor 
pathways (Font and Brown, 2000), has been linked to poor prognosis in Tamoxifen 
treated ERa positive patients (Osbome et al., 2003). In addition levels of the co­
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repressor N-CoR was reduced in an animal model of tamoxifen resistance (Lavinsky 
et al., 1998).
Other oestrogen-like effects of Tamoxifen may stem from ERa action at genes with 
alternative non-classical response elements such as AP I or Sp-1 sites (Saville et al.,
2000). For example ERa has been shown to enhance AF-1 activity in the presence of 
tamoxifen (Weatherman and Scanlan, 2001; Webb et al., 1999).
1.4.5 Development of ligand independent ER mediated transcription
The concept of ligand independent activation of ERa, particularly in regard to 
activation of the AF-1, has already been discussed. There is considerable evidence 
that ligand independent activation can follow the activation of components of growth 
factor pathways such as MAPK, JNK kinase (Font and Brown, 2000; Kato et al., 
1995) (Feng et al., 2001) or AKT (Campbell et al., 2001). Activation of the normally 
quiescent AFl region may promote gene transcription even in the presence of 
tamoxifen (Figure 5).
< TAM  >
PROMOTER REGION GENE
Figure 5 Altered transcription; fos, jun, myc, cyclin D, cdk inhibitors
Phosphorylation o f AF-1 region by components o f  growth factor pathways may lead 
to ligand independent activation despite presence o f Tamoxifen.
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Evidence for the role of the HER family in this process and in development of 
subsequent Tamoxifen resistance will be discussed in the following chapters. 
However cell lines acquiring oestrogen independence often retain their responsiveness 
to anti-oestrogens (Clarke et al., 1989) thus it may be that oestiogen independence 
and anti-oestrogen resistance involves overlapping but separate mechanisms.
1.4.6 Role of Growth Factors.
Growth factors have been shown to produce oestrogen-like effects in ER positive 
breast cancers even in the absence of oestrogenic stimuli (Bunone et a l, 1996; El 
Tanani and Green, 1997). Thus growth factor signalling may play a critical role in 
regulating the response of breast cancer cells to both oestrogens and anti-oestrogens. 
Wliilst tamoxifen blocks the oestrogenic induction of growth factors such as TGF-a, 
IGF-1 and EGF (Dickson and Lippman, 1995), it also induces the secretion of the 
growth inhibitoiy factor TGF-pl (Knabbe et a l, 1987) suggesting the promotion of a 
inhibitory autocrine loop. However tamoxifen resistant MCF7 cells have been shown 
to overexpress TGF-pl (Herman and Katzenellenbogen, 1996; Arteaga et a l, 1999) 
and reversal of TGF-j31 activity can restore tamoxifen sensitivity in vitro (Arteaga et 
a l, 1999). Indeed, whilst treatment with exogenous TGF-p inhibits breast cancer cell 
proliferation (Knabbe et a l, 1987) it can also stimulate MAPK (Frey and Mulder, 
1997; Visser and Themmen, 1998) associated tumour growth.
In addition in patients who do not respond to tamoxifen, TGF-P2 levels increase 
before clinical detection of recurrence implying resistance to any growth inhibitoiy 
effects(Kopp et a l, 1995). Overexpression of TGF-p2 can suppress natural killer 
(NK) cell function and inhibition of TGF-p2 restores NK cell function and tamoxifen
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sensitivity in vivo (Arteaga et a l, 1999). This suggests TGF-P2 overexpression may 
affect resistance through immunological mechanisms.
Another growth factor family that has stimulated interest with respect to tamoxifen 
resistance is the insulin like growth factors. Both IGF-I receptors (IGF-I-Rs) and IGF- 
II receptors (IGF-II-Rs) are expressed in breast tumours (Papa et a l, 1993) but in the 
context of tamoxifen resistance most attention is focussed on IGF-I-R because of 
evidence of crosstalk with the ER (Lee et a l, 1999). More recently studies have 
shown an alteration of insulin-like growth factors-binding proteins (IGF-BP) that 
generally inhibit IGF function with IGFBP-2 demonstrated as a marker for 
antiestrogen resistant breast cancer cell lines, although not necessarily a contributor to 
the resistant cell growth (Juncker-Jensen et a l, 2006). Unlike other growth factors, 
IGF-IR expression appears to be positively correlated with ERa expression in breast 
cancer and recent work has suggested that it may be involved in activation of 
membrane bound ERa (Razandi et a l, 2003b). In addition it has been suggested that 
IGF-IR is a key component involved in acquisition of resistance to the anti-EGFR 
small molecule inhibitor gefinitib in tamoxifen resistant cells (Hutcheson et a l, 2006). 
The HER family of tyrosine kinase growth factor receptors has also been implicated 
in the development of tamoxifen resistance and will be discussed in more detail in the 
next section.
1.4.7 Estrogen Regulated genes; TFFl (pS2) and PR
PS2 (TFFl) and PR aie both estrogen regulated genes. The expression of TFFl is 
regulated through an ERE and expression PR through a Spl recognition site on the 
progesterone receptor (PR) gene. The pS2 gene is often used in breast cancer in 
studies of ER action/activation (Krieg et a l, 2004)
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In terms of predicting response to tamoxifen, cytosolic expression of trefoil protein 
TFFl (previously known as pS2), has been shown to be linked to good outcomes and 
endocrine responsiveness (Corte et al., 2006; Gion et al., 1993) in some studies but 
not in others (loachim et al., 2003; Elledge et al., 2000).
The evidence for PR in predicting tamoxifen response has drawn conflicting 
conclusions over the years. Certainly PR expression has been thought to demonstrate 
an intact, functioning ER pathway. The large Oxford overview did not confirm PR as 
a predictive marker for tamoxifen response (Early Breast Cancer Trialists' 
Collaborative Group, 1992) however a retrospective analysis of a large dataset with 
standardised methodology demonstrated that ER/PR positive patients showed better 
outcomes on tamoxifen than ER positive/PR negative patients in multivariate analysis 
(Osbome et al., 2005; Bardou et al., 2003). In keeping with this, the AT AC trial 
suggests an increased benefit of tamoxifen over aromatase inhibitor in PR negative 
patients (Dowsett et al., 2005). In addition, unlike ER, sequential biopsies suggest that 
PR levels may decrease dramatically with up to half of tumors completely losing PR 
expression when resistance to endocrine therapy evolves (Gross et al., 1984) 
suggesting a potential model for acquired resistance. The expression of different PR 
isoforms as predictors of tamoxifen response may also be of importance. 
Overabundance of PR-A has been associated with resistance to tamoxifen (Hopp et 
al., 2004a) while a functional polymorphism resulting in increased production of PR- 
B may be associated with an increased risk of breast cancer (De, I et al., 2003).
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1.5 Human Epidermal Growth Factor Receptor 
(HER) Family
1.5.1 HER 1-4 family; 4 closely homologous receptors
Evidence has suggested that Tamoxifen resistance may involve cross talk between the 
HER family and the ERa (Schiff et al., 2004). The HER family of tyrosine kinases 
receptors lies at the head of a complex signal transcription cascade which modulates 
cell proliferation, survival, adhesion, migration and differentiation. This multi-layered 
signalling network provides an opportunity for a potentially huge diversity of 
signalling messages. The family is comprised of 4 closely homologous receptors 
HERl (ErbBl/EGFR), HER2 (ErbB2/neu), HER3 (ErbBS) and HER4 (ErbB4). 
Growth factor-induced HER signalling is essential for normal cellular processes 
however it also plays a key role in the aberrant development and growth of tumour 
cells (Yarden, 2001b).
The HER receptors are trans-membrane receptors. Each HER family member is 
composed of an extracellular ligand binding domain, a lipophilic transmembrane 
segment and cytoplasmic tyrosine kinase region with a regulatory carboxy-terminal 
segment (Ullrich and Schlessinger, 1990; van der Geer P. et al., 1994). Ligand 
binding to the extracellular domain induces the receptors to form hetero- or homo­
dimers. Cross-phosphorylation of the tyrosine residues then occurs resulting in the 
docking sites for signalling complexes. The subsequent release of enzymes and 
adapter proteins into the cytoplasm stimulates multiple signal transduction cascades. 
Three layers of interaction have been identified as being key factors in the generation 
of the diverse pattern of signalling messages (Alroy and Yarden, 1997) (Figure 6).
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1. Firstly, 2 main groups have been identified as HER ligands (Mendelsohn and 
Baselga, 2000). There are 6 direct ligands of HERl. Epidermal growth factor 
(EGF), amphiregulin and transforming growth factor alpha (TGFa) only bind to 
HERl. Heparin binding EGF (HB-EGF), betacellulin, and epiregulin can bind to 
both HERl and HER4. A second class of ligand called neuregulins bind to HER3 
and HER4. Neuregulin-1 and -2  bind to either receptor, while neuregulin-3 and - 
4 bind to HER4 only. Recent work has shown that 2 different ligands activating 
the same receptor can have a differential impact on transcriptional outcome (Amin 
et a l, 2004).
2. Secondly, each of the ligands has a different preference for stabilising particular 
receptor dimers. Yarden et al created cell lines co-expressing a combination of 
HER family receptors. The mitogenic index of each dimer was compared and the 
most active signalling complex was between HER2 and HER3 (Yarden, 2001a). 
In general heterodimers generate more potent signals than homodimers (Alroy and 
Yarden, 1997).
3. Thirdly, each ligand receptor dimer directs its signal through a unique but 
overlapping set of signalling pathways (Olayioye et a l, 2000). These signal 
transduction cascades include the MAPK pathway, PKC, phosphoinositol kinase, 
Akt and several transcription regulators. Ultimately these signals reach the 
nucleus and lead to nuclear gene activation.
Further complexity is highlighted by the fact that HER2 enhances and stabilises 
dimerization but apparently has no ligand (Klapper et a l, 1999) whereas HER3 has no 
inherent kinase activity so must be dinierised with another HER family member to 
exert an influence on downstream signalling (Guy et a l, 1994).
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Figure 6
Multiple layers o f interaction have been identified as being key factors in the 
generation o f the diverse pattern o f signalling messages.
1.5.2 Role of the HER family in normal breast.
The HER family is involved in the regulation of normal breast growth and 
development (DiAugustine et al., 1997; Carraway et al., 1997). Their ligands have 
been shown to stimulate the lobulo-alveolar development of the mouse mammary 
gland in explant cultures and in vivo (Jones et al., 1996). Identifying the individual 
role of each receptor is complex, especially with the presence of multiple ligands 
(Stem, 2003). However, in mouse, HERl and HER2 are abundant prior to puberty 
and during subsequent developmental stages whereas HER3 and HER4 are at low 
levels prior to maturity (Schroeder and Lee, 1998; Sebastian et al., 1998). All 4 HERs 
are evident throughout pregnancy and lactation (Schroeder and Lee, 1998).
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1.5.3 Role of the HER family in breast cancer.
Dys-regulation of all 4 members of the HER family has been demonstrated in a 
variety of human cancers.
1.5.3.1 EGFR/HERl
HERl is a IVOkD transmembrane receptor that is expressed on the surface of most 
cell types and is located on human chromosome 7q21. HERl is expressed in a variety 
of human cancers, including non-small cell lung cancer, head and neck, gastric, 
colorectal, oesophageal, prostate, bladder, renal, pancreatic and ovarian cancers 
(Salomon et a l, 1995). The HERl ligand EGF was shown to be a potent mitogen in 
the breast cancer cell line MCF-7 (Osbome et a l, 1980) and the first reports of HERl 
expression in human breast cancers were in 1985 (Sainsbury et a l, 1985).
Sainsbury et al were also the first to identify a link between HERl and prognosis in 
breast cancer (Sainsbury et a l, 1987). Since then, many studies have examined this 
relationship, not always with conclusive results (reviewed (Klijn et a l, 1992) and 
(Nicholson et a l, 2001a)). One of the largest studies was recently performed using 
immunohistochemistry in 1029 patients (Tsutsui et a l, 2002). Multivariate analysis 
demonstrated that HERl was an independently significant prognostic factor for 
disease free and overall sum val Certainly we know there is a significant negative 
correlation between EGFR positivity and ER status (Koenders et a l, 1991).
There has also been speculation as to the future of HERl as a predictive factor for 
selection of various treatment modalities. ZD1839 (Iressa) is an orally active selective 
HERl tyrosine kinase inhibitor which has shown promise in preclinical trials, and is 
currently undergoing phase R clinical trials in breast cancer (Morris, 2002). High
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expression of HERl has been associated with resistance to radiotherapy (Sartor, 2000) 
and its putative role in Tamoxifen resistance will be discussed later.
1.5.3.2 HER2
The HER2 proto-oncogene encodes an 185kD transmembrane glycoprotein and is 
mapped to chromosome 17q21. Despite apparently having no ligand, HER2 
homodimers form avidly and HER2 is the prefened dimerization pailner for other 
HER members (Graus-Porta et al., 1997; Tzahar et al., 1996). This may help explain 
the high oncogenic potential of HER2. HER2 heterodimers have particularly high 
ligand-binding and signalling potency (Sliwkowski et al., 1994) with the most potent 
dimer in terms of cell growth and transformation being HER2-HER3 (Pinkas- 
Kramarski et a l, 1996). It has been proposed (Klapper et al, 1999) that HER2 maybe 
the ultimate co-ordinator of the signalling network, amplifying signalling by multiple 
ligands.
HER2 is normally expressed in a variety of cell and tissue types and is frequently 
overexpressed in a number of human cancers (Hynes and Stem, 1994). HER2 
overexpression and amplification is found in lung, gastric and ovarian cancers 
(Schneider et al., 1989; Yoshida et a l, 1989; Berchuck et a l, 1990).
Both preclinical and clinical studies indicate that HER2 amplification and 
overexpression is involved in oncogenic transformation and tumorigenesis in breast 
cancer. Cell lines that overexpress the HER-2 gene product display a highly 
transformed and tumorigenic phenotype as compared with control cells (Chazin et a l, 
1992; Di Fiore et a l, 1987). In addition HER2 gene amplification or protein 
overexpression has been demonstrated in 15-30% of invasive breast cancers (Berger 
et a l, 1988; Slamon et a l, 1987). The majority of cases of HER2 overexpression
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appear to be as a consequence of HER2 gene amplification (Pauletti et a l, 1996). 
Slamon et al (Slamon et al., 1987) first linked HER2 with poor prognosis in breast 
cancer in 1987. Since then there have been multiple studies investigating this 
relationship. A meta-analysis of 47 trials (Ross and Fletcher, 1998) demonstrated 
HER2 was an independent predictor of prognosis in 60% of the trials involving 67% 
of patients. Of note all the studies that used FISH to detect gene HER2 amplification 
concluded that there was a clear association between HER2 status and prognosis. 
Herceptin (trastzumab) is a HER2 monoclonal antibody against its extracellular 
domain. Patients with strongly HER2-positive metastatic breast cancer derive 
significant clinical benefit from single-agent and combined Herceptin therapy 
(Baselga, 2001) in the metastatic setting for HER2 positive patients. More recently 
interim results from the BIG HERA trial suggest significantly improved disease free 
suiwival with reduction in distant metastasis in HER2 positive patients given adjuvant 
Herceptin for 1 year (Piccart-Gebhart et al., 2005).
1.5.3.3 HER3
In 1989 a S*'* member of the HER family was identified (Kraus et al., 1989) as a 148- 
IcDa transmembrane polypeptide mapped to chromosome 12ql3. Due to substitutions 
in critical residues in its catalytic domain, HER3 has an impaired kinase (Guy et ai.,
1994), and thus can only process its signalling in the context of a receptor 
heterodimer. HER3 is found in cells of the developing gastrointestinal, reproductive 
and urinary tracts as well as the skin, endocrine and nervous systems (Prigent et a l, 
1992). HER3 is expressed in tumours of the skin, ovaiy and gastrointestinal tract 
(Bodey et a l, 1997; Maurer et a l, 1998; Simpson et al, 1995). There is also evidence 
for its role in breast cancer. Markedly elevated HER3 niRNA levels have been
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demonstrated in certain human mammary tumour cell lines (Kraus et a l, 1989). In 
addition HER3 has been demonstrated to be overexpressed in 15 -52%  of breast 
cancers (Lemoine et a l, 1992; Naidu et a l, 1998; Travis et al, 1996).
Conflicting evidence has been produced on the prognostic significance of HER3. 
Some (Witton et a l, 2003; Naidu et a l, 1998; Tovey et a l, 2004; Travis et a l, 1996) 
have demonstrated a relationship between HER3 and markers of poor prognosis in 
breast cancer. Others have concluded that HER3 overexpression is consistent with a 
good prognostic outlook (Pawlowski et a l, 2000).
1.5.3.4 HER4
HER4 deserves particular attention when examining the role of the HER family in 
breast cancer as there is now substantial evidence suggesting that it may play a 
protective role in breast cancer in contrast to the other family members. The 
HER4/erbB4 gene encodes a 180-kDa transmembrane tyrosine kinase (Plowman et 
a l, 1993) on chromosome 2 (Zimonjic et a l, 1995). HER4 is widely expressed in 
many adult and foetal tissues and is generally found in the differentiated 
compartments (Srinivasan et a l, 1998). In normal breast tissue HER4 appears to play 
a critical role in the late differentiation of mammary gland function (Jones et al,
1999) especially during pregnancy and lactation (Tidcombe et a l, 2003). This is 
consistent with data from cell lines showing that whilst HER4 can support 
proliferation and transformation, in some lines it has also been shown to induce 
growth arrest and differentiation (Sartor et a l, 2001; Williams et a l, 2003). Recently, 
evidence, again from cell lines using agonistic monoclonal antibodies, showed the 
HER4 antibody inhibited cell growth in contrast to the HER2 antibody which 
stimulated growth (Amin et a l, 2004). Using a global gene-expression monitoring
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system, they also reported that activation of HER2 or HER4 in the same cell line 
differentially activated gene transcription.
The evidence for a role for HER4 in tumorigenesis is scanty. One small study looking 
at solid tumours demonstrated overexpression in some adenocarcinomas and a loss of 
expression in squamous cell carcinomas (Srinivasan et al, 1998). Certainly HER4 is 
expressed in several breast cancer cell lines (Plowman et a l, 1993). Studies have 
demonstrated the expression (29 -82%) of the HER4 protein in breast cancers 
(Srinivasan et a l, 1998; Srinivasan et a l, 2000; Suo et a l, 1998; Suo et a l, 2002) 
although they also suggested that this expression may be decreased when compared to 
normal breast tissue. Gene amplification has been demonstrated in 13% of breast 
cancers (Vogt et a l, 1998).
We have recently shown that, in contrast to other HER family members, HER4 
expression is associated with increased suiwival and lower proliferation indices 
(Tovey et a l, 2004; Witton et a l, 2003). These results are supported by data linking 
HER4 to established good prognostic indicators such as a lower grade of tumour 
(Kew et a l, 2000; Srinivasan et a l, 2000), ER positivity (Pawlowski et a l, 2000) and 
low proliferation indices (Knowlden et a l, 1998). However, whilst other groups have 
also demonstrated a link between HER4 positivity and a longer disease free interval 
(Suo et a l, 2002) there have also been conflicting reports associating HER4 with an 
adverse prognostic significance (Lodge et a l, 2003). More recently there has been 
evidence from a large series of patients suggesting that the prognostic value of HER4 
overexpression is dependent on coexpression with other HER family members (Abd 
El-Rehim et a l, 2004). In this study, when the group was looked at as a whole, HER4 
status was not related to survival. However in cases showing expression of one family
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member only (homodimers), they found a significant association between HER4 
homodimer-expressing tumours and improved disease free survival.
There are intrinsic problems in comparing these studies and their outcomes. Different 
cut-off points for positivity have been chosen depending on the study and the 
modality of staining looked at (membrane, cytoplasm, and nuclear). Some groups 
have reported staining in all 3 locations, whilst others have found no membranous 
(Lodge et al., 2003) or no nuclear staining (Suo et al., 2002). Three different 
antibodies have been used in these studies. The HFRl clone developed by the Gullick 
group has been the most widely used (Kew et al., 2000; Lodge et al., 2003; Srinivasan 
et al., 1998; Srinivasan et al., 2000; Abd El-Rehim et a l, 2004). This group 
demonstrated the ability of this antibody to recognise HER4 by immunoprécipitation, 
western blotting and immuno-staining of NH3T3 cells transfected with HER4. They 
demonstrated no cross-reactivity with EGFR using A431 cell lysates or with HER3 or 
HER4 using lysates from SKBR3 or 293/HER3 cells. A SantaCruz antibody C l8 has 
also been used by one group (Suo et a l, 2002). In our previously study on frozen 
tissue we used a Neomaikers antibody H4.77.16.
Recent studies have substantially enlianced our understanding of the many functions 
of HER4. Indeed, as well as acting as a membrane signal transduction receptor, 
nuclear HER4 is required for mammary gland development and lactation though gene 
regulation in conjunction with STAT5A (Clark et al, 2005; Williams et a l, 2004), 
and mitochondrial HER4 has been shown to mediate apoptosis in the mitochondria 
via BAK (Vidal et a l, 2005).
Recent evidence suggests that, as with HER2 and EGFR, the HER4 protein can be 
enzymatically cleaved, which may markedly alter the function of the intracellular 
domain of the receptor. Cleavage occurs within the juxtamembrane region through the
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activity of TNTa-converting enzyme (TACE) followed by further proteolytic 
processing by presenilin-dependent y-secretase activity (Lee et a l, 2002; Rio et a l,
2000) to release the cleaved intracellular domain (4ICD). Indeed this 4ICD has been 
shown to harbour a BCL-2 homology 3 (BH3)-domain and independently function as 
a BH3-only protein (pro-apoptotic members of the BCL-2 family required to initiate 
mitochondria dysfunction) so mediating cellular apoptosis. However it has also been 
demonstrated in the nucleus acting as a chaperone for STAT5A (Williams et a l,
2004) to alter gene regulation. Thus, it is essential to determine both the location and 
intensity of staining for HER4 in order to fully understand its’ function in vivo. 
Indeed, one recent study using the HFRl antibody demonstrated very different 
correlations in terms of survival depending on cellular location of HER4 staining. 
Whilst membranous HER4 was associated with a good prognostic outlook, nuclear 
HER4 was associated with significantly shorter sum val times (Junttila et a l, 2005). 
Thus one possible explanation for the conflicting reports on HER4 and its association 
with survival may be that the results are antibody dependent. HFRl, the antibody 
developed by the Gullick group recognises the intracellular domain of HER4 and is 
thus able to recognise both the intact receptor and the cleaved ICD as it traffics 
through the cell. However the H4.77.16 clone recognises an extracellular domain of 
HER4 and thus, on tissue sections, detects the full length receptor not the cleaved 
ICD. The variance in reported results for in vivo analysis of HER4 expression may be 
a reflection of differing antibody specificities, especially with respect to the intra­
cellular and extra-cellular domains of the protein. Certainly we know that even for 
established diagnostic markers such as ER and PR within laboratories participating in 
external quality assessments (EQAs) there are still problems with technical validation 
and standai'dization (Rhodes et a l, 2001).
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1.5.3.5 HERl-4 acting in combination
As discussed with regard to HER4, one of the problems with the above analysis is the 
examination of these receptors in isolation, whereas in reality expression of multiple 
receptors may result in a synergistic or an additive response. We know that cancers 
that overexpress HERl or HER2 in combination have a worse prognosis than those 
which are positive for only one receptor (Tsutsui et al, 2003). In contrast when HER2 
and HER4 are co-expressed there is a reduced risk of relapse and death compared to 
tumours where HERl and 2 are overexpressed (Suo et al, 2002; El Tanani and Green, 
1997). This suggests that HER4 may be able to antagonise the HER2 effect on poor 
clinical outcome. In cell lines high levels of HER2 expression alters the ability of 
HERl tyrosine kinase inhibitors to inhibit HERl phosphorylation (Christensen et a l,
2001), In terms of potential treatments, whilst we know HER2 amplified tumours can 
be successfully treated with Herceptin (Piccart-Gebhart et a l, 2005; Smith et a l, 
2007), we don’t know how co-expression of other HER family members may 
influence this response.
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1.6 Relationship between HERl-4 and resistance to 
tamoxifen
Most studies in this field have investigated Tamoxifen resistance in the context of 
HERl and HER2 overexpression.
1.6.1 Experimental studies
Benz et al (Benz et a l, 1993) took oestrogen positive, hormonally sensitive MCF-7 
cells and transfected them with very high levels of HER2. Despite the cells remaining 
oestrogen dependent they became resistant to Tamoxifen. Other studies (Pietras et al,
1995) using HERl and HER2 showed similar results but found that tumour cell 
growth became independent of oestrogen with a downregulation of ERa. Pietras et ai 
and others have also demonstrated that inhibitors against HER2 and HERl can restore 
Tamoxifen sensitivity in HER2 overexpressing tamoxifen resistant cells (Kurokawa et 
a l, 2000).
Furthermore MCF-7 cells which over time had become resistant to tamoxifen were 
demonstrated to have increased levels of both HERl and HER2 compared to 
Tamoxifen responsive cells (Nicholson et a l, 2001b; Knowiden et a l, 2003). Again 
cell growth in these models was significantly reduced with the use of the HERl 
inhibitor (Iressa) and HER2 antibody (Herceptin).
1.6.2 Clinical studies
There has been a multitude of studies reporting on the proposed influence of HER2 
expression on hormonal resistance, but results are varied and confusing. Some studies
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have demonstrated a clear link with resistance (Bems et al, 1995; Borg et a l, 1994; 
Carlomagno et a l, 1996; Houston et a l, 1999; Leitzel et al, 1995; Yamauchi et al, 
1997; Wright et a l, 1992). Others have not demonstrated any association (Elledge et 
al, 1998; Soubeyran et a l, 1996; Berry et a l, 2000; Knoop et a l, 2001; Archer et a l,
1995).
The picture for HERl is equally unclear. Some studies have indicated a positive link 
with Tamoxifen resistance (Newby et a l, 1997; Nicholson et a l, 1994) with others 
not showing any significant difference (Knoop et a l, 2001).
Several explanations have been proposed for this conflicting evidence (Dowsett, 
2001; Elledge e ta l ,  1998).
1. Several of the studies included ERa negative or ERa unknown tumours in their 
analysis (Carlomagno et a l, 1996; Leitzel et a l, 1995) which will not respond to 
tamoxifen and are also more likely to be HER2 or HERl positive. Often when the 
results are substratified for ERa status any significant association is lost 
(Nicholson et a l, 1994).
2. Multiple treatment settings were analysed including neoadjuvant (Soubeyran et 
a l, 1996), metastatic (Leitzel et a l, 1995) and local recurrence (Houston et al.,
1999).
3. Only a small group of patients will be both ER and HERl/2 positive which makes 
it difficult to achieve statistical power in a study. Some studies have shown that as 
little as 10% of tumours are ERa and HER2 positive with the percentage even 
lower for HERl (Dowsett, 2001).
4. Chemotherapy is also routinely given to many of these patients, which may 
interact with HER2 status. For example it has been suggested that anthracyline 
therapy may overcome HER2 induced resistance.
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5. Multiple methods have been used to measure HER2 status with a variety of cut­
offs for positivity such as IHC (Elledge et a l, 1998), FISH (Beny et a l, 2000) and 
serum measurements (Leitzel et a l, 1995).
6. The duration of Tamoxifen therapy varied. Some studies only examined the 
follow-up with Tamoxifen treatment after one year which may not be long enough 
for a resistance pattern to develop (Knoop et a l, 2001).
It is likely that the limited statistical power of these studies together with the inclusion 
of ER negative cases explains the majority of these conflicting results and it would be 
important to address these points in planning a future in vivo study examining any 
association between the HER family and tamoxifen resistance.
There is little in vivo or in vitro evidence currently to link HER3 and HER4 to 
tamoxifen resistance (Larsen et a l, 1999; Knowlden et a l, 1998), although similar 
signalling pathways are activated by H ER l-4.
1.6.3 Aromatase Inhibitors versus Tamoxifen
Some of the most convincing clinical evidence for the role of HERl and 2 in 
tamoxifen resistance has come from neo-adjuvant trials where HERl/2 positive 
patients have significantly greater response to aromatase inhibitors than to Tamoxifen 
(Ellis et a l, 2001). Whilst there is no definite evidence that this is also the case in the 
adjuvant setting from trials so far, this is now being built into subtrial analysis 
(retrospectively for the AT AC trial and prospectively for TEAM (Tamoxifen 
Exemestane Adjuvant Multinational)). Certainly data from the AT AC (Dowsett,
2003) and lES trials (Coombes et a l, 2004a) suggest that some differences do exist in 
the molecular profile of patients who respond to early or to delayed treatment with
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aromatase inhibitors. In the ATAC trial PR negative patients derived greater benefit 
from initial aromatase inhibitor treatment compared to Tamoxifen. However PR status 
had no impact on response when aromatase inhibitors were given as delayed treatment 
to patients who had been disease free on Tamoxifen for 2-3 years (IBS). Whether the 
negative PR is acting as a suirogate marker for H ERl-3 overexpression in the AT AC 
trial remains to be seen but we do know that, as with ERa, there is an inverse 
relationship between PR expression and HER2 expression (Marsigliante et al., 1993; 
Quenel et al., 1995).
Further evidence on the relative importance of other growth factor receptors, 
including HERl, 3 & 4 are required before these findings alter clinical practice, 
particularly in the adjuvant setting.
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1.7: Cross talk between ER and HER pathways:
Relationship with Tamoxifen resistance?
Whilst some have argued that the mechanisms behind the HER families’ role in 
Tamoxifen resistance is due to a dislocation of the growth factor stimulated pathways 
from ER signalling, this is disputed by the fact that switching to another fomi of 
endocrine therapy can overcome resistance patterns both in vitro and clinically. Thus 
it is likely that ER signalling remains involved.
Several mechanisms have been proposed by which the type I RTKs may modify 
response to oestrogens and tamoxifen. There is a considerable body of biological 
evidence suggesting that this cross talk occurs at multiple levels and appears to be bi­
directional (Nicholson et al., 1999).
The most obvious relationship between the HER family and ERa status appears to be 
a negative one. Certainly tumours positive for H ERl-3 tend to be ERa negative 
(Witton et al., 2003) and, in the case of EGFR, it has also been suggested that at an 
individual cell level EGFR and ERa are mutually exclusive (Sharma et a l, 1994). 
This may partially be explained by an active mechanism at a transcriptional level 
whereby oestrogen suppresses EGFR (Yarden et al, 2001; Wilson and Chrysogelos,
2002) or HER2 (Newman et a l, 2000).
However we also know that oestrogen and EGFR can also have a stimulatoiy effect 
on each others pathways. In several ERa positive breast cancer cells lines it has been 
shown that oestrogen is able to transiently induce EGFR expression (Yarden et a l,
1996). Some evidence has suggested that oestrogen induced growth factor pathway 
stimulation may be via ‘non classical pathways. For example recent studies have
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demonstrated the ability of oestrogen to stimulate activation of the MAPK and PIK3 
pathways independently of gene action (Migliaccio et a l, 1996; Simoncini et al.,
2000). Alternatively there may be interaction with sites such as Spl (Salvatori et al.,
2003) resulting in direct transcriptional action of ERa on the EGFR gene.
In addition, the growth factors TGFa and EGF can produce oestrogenic effects in ER 
positive cells in the absence of oestrogenic stimuli (i.e. ligand independent activation) 
(Bunone et al., 1996; El Tanani and Green, 1997). Again recent evidence suggests 
that this interaction may be in a non-genomic manner (Razandi et al., 2003b) possibly 
involving interactions at the cell membrane (Chung et al., 2002). Ultimately though, 
irrespective of location, there still needs to be an endpoint by which the growth 
factors or their down stream effectors may manipulate ERa activation. As discussed 
eaiiier, oestrogen receptors are phosphoproteins (Shao and Lazar, 1999) and whilst 
ligand binding controls AF2 activity, AFl activity is regulated by phosphorylation at 
sites including serine 104/106, SI 18 and S167. (Ali et a l, 1993; Le Goff et a l, 1994; 
Smith, 1998; Arnold et a l, 1994). The potential of ERa to be modulated by 
phosphorylation provides a key mechanism by which the HER signal transduction 
pathways may influence ERa transcription. Multiple pathways activated by the HER 
receptors have been identified, which are often interlinked (Jorissen et a l, 2003). 
These pathways may provide the means by which a growth factor signal at the cell 
surface results in ERa phosphorylation and subsequent modulation of its functions 
including DNA binding and transcriptional activation despite the presence of 
tamoxifen. The cellular proliferation Ras/MAPK pathway and the survival/anti- 
apoptosis PI3-K/AKT pathway are both generating the most interest in terms of anti- 
oestrogen resistance mechanisms.
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1.7.1 Mitogen-activated protein kinase (MAPK) pathway
Growth factors acting via tyrosine kinase receptors activate MAPK by first the 
GTPase Ras then subsequent serine-theonine kinase Raf-1 activation (Hill and 
Treisman, 1995). The MAPK pathway is a key phosphoiylation cascade by which 
growth factor signal transduction is conveyed from the plasma membrane to the 
nucleus (English et al., 1999) (figures 6 & 7). The MAPKs phosphorylate and thereby 
modify the function of numerous proteins including those regulating cell cycle 
checkpoints and gene transcription (Chang and Karin, 2001). In the nucleus MAPK 
activates transcription factors such as myc and Elkl. Under normal conditions 
activation of the MAPK pathway is transient and attenuated by many control 
mechanisms including inactivating phosphatases (Keyse, 2000; Pearson et al., 2001). 
The control however may become lost and several lines of evidence suggest that 
dysregulation of this pathway may have particular significance in breast 
carcinogenesis.
MAPK activity has been shown to elevated in breast tumours often with upregulation 
of its gene expression (Sivaraman et a l, 1997) and has been associated with decreased 
survival (Mueller et a l, 2000). Phosphorylated MAPK positivity (identified using 
IHC) has been associated with a poor response to Tamoxifen therapy (Gee et al,
2001) in ERa positive tumours. Similar results have been demonstrated in vitro where 
HER2 driven MAPK elevation has been associated with Tamoxifen resistance 
(Kurokawa et a l, 2000; Benz et a l, 1993).
The serine phosphoiylation site SI 18 in the AFl region of the ER has been found to 
be a target for phosphorylation by MAPK (Kato et a l, 1995; Bunone et a l, 1996). 
Work using cell line mutants has identified a key role for SI 18 in oestrogen - 
independent MAPK activation of ER (Atanaskova et a l, 2002; Chen et a l, 2002).
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However there also seems to be a role for ligand dependent (via oestrogen and to a 
lesser extent tamoxifen) activation of SI 18 which does not require MAPK (Chen et 
al., 2002). Thus it is postulated that oestrogen and also tamoxifen activation of the 
AFl region can be enhanced/circumvented by MAPK mediated growth factor 
signalling. This may provide a potent explanation for Tamoxifen and other anti­
oestrogen resistance.
However some studies indicate this ligand-independent signalling does seem to retain 
the ability to be inhibited by Tamoxifen (Atanaskova et al., 2002), suggesting that the 
this is method of signalling may not be sufficient to induce anti-oestrogen resistance 
on its own.
1.7.2 PhospatidyIinositol-3 kinase (PI-3K) and Akt pathway
The phospatidylinositol-3 kinase (PI-3K) and Akt pathway is known to have a key 
role in the cell survival (anti-apoptosis pathway) (Franke et a l, 1997). Akt (protein 
kinase B) is a member of a conserved family of serine/theonine protein kinases that 
includes Aktl, Akt2 and Akt3 (Alessi and Downes, 1998). Activation of 
tiansmembrane growth factor receptors results in the recruitment of PI3 kinase to the 
plasma membrane (Datta et a l, 1999). PI3 kinase subsequently promotes the 
generation of phosphorylated phosphoinositides which then bind and activate Akt 
(Campbell et a l, 2001; Chan et a l, 1999). It appears that HER3 in particular has a 
strong link to the Akt pathway with 6 binding sites being identified for PI3-K 
(Carraway, HI and Cantley, 1994).
Activated Akt then plays a key role in cell survival by phosphoiylating and hence 
modulating the activity of various transcription factors at the nucleus. Akt has been 
demonstrated to suppress apoptosis. Mechanisms for this include phosphoiylation
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(and hence inhibition of action) of the pro-apoptotic proteins BAD and capase-9 
(Cardone et a l, 1998; Datta et a l, 1997). Thus disruption of the Akt pathway may 
well result in tumour growth. Indeed cell lines with constitutively activated Aktl 
undergo malignant transformation (Sun et a l, 2001b).
Various studies have implicated members of the AKT pathway in the pathogenesis of 
breast cancer. Aktl kinase activity has been demonstrated in high grade breast cancers 
(Sun et a l, 2001b). Akt2 gene amplification has been reported in a small percentage 
of breast cancers (Bellacosa et a l, 1995) and Akt3 mRNA is elevated in ERa negative 
breast cancers (Nakatani et a l, 1999).
PTEN is a phospholipid phosphatase tumour suppressor gene that normally attenuates 
the Akt survival signal (Cantley and Neel, 1999) by dephosphoiylating 
phosphatidylinositol-triphosphate (PtdlnsP) and suppresses cell growth through the 
negative regulation of cell cycle and cell survival. Downregulation of PTEN is 
associated with increased PI3 kinase activity with subsequently higher levels of 3'- 
phosphorylated phosphoinositides, which bind to and activate PK-B/Akt. Reduced 
expression of PTEN has been demonstrated in high grade breast cancers (Bose et a l,
2002) and has recently been associated with relapse-free smwival and disease-specific 
suiwival in tamoxifen treated ER positive patients (Shoman et a l, 2005).
There is evidence that the Akt pathway may also mediate signalling from the growth 
factor receptors to the ERa (Martin et a l, 2000). Constitutively active Akt has been 
shown to induce ER reporter activity in the absence of oestradiol (Kurokawa and 
Arteaga, 2003) and MCF-7 cells overexpressing AKTa were not as sensitive to 
inhibition by Tamoxifen compared to wild type cells (Campbell et a l, 2001). Studies 
using cell lines with mutated serine residues have demonstrated that Akt mediates its 
action on the ERa by phosphorylation of serine residue Seri 67 in the AFl region.
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This again occurs in a ligand independent manner (Campbell et a l, 2001; Martin et 
a l, 2000).
Thus there is evidence that both the Akt and MAPK pathways may mediate the ERa -  
HER crosstalk leading to anti-oestrogen resistance in breast cancer. Again a limitation 
of examining these pathways independently is that they do not act in isolation. For 
example Akt has been shown to inhibit the Raf-MEK-MAPK pathway through 
phosphoiylation of Raf-1 (Zimmermann and Moelling, 1999). Ras has also been 
shown to bind and activate a subunit of PI3-K (Pacold et a l, 2000) and Akt activation 
is partially dependent on the activity of Ras
1.7.3 Continuous cycling of growth factor signalling stimulated ERa activation?
These in vitro results suggest the possibility that continuous cycling between a ligand- 
independent activated ERa and growth factor signalling could develop (Clarke et a l, 
2001a) so promoting unopposed tumour growtli. So where would tamoxifen fit into 
this cycle? As discussed previously. Tamoxifen acts by targeting the AF2 but not the 
AF-1 regions of the ERa. Should the AF-1 region become involved in ligand 
independent mediated activation this would provide a mechanism by which growth 
factor pathway stimulation of the ERa could occur with no mechanism for Tamoxifen 
to antagonise it (Figure 7).
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Figure 7
Cross talk between the HER family and phosphorylation sites o f the A F l region o f the 
ER may result in ligand independent activation.
More recently it has been suggested that ERa located at the membrane may directly 
signal via activation/cross talk with HERl (Razandi et al., 2003b). High levels of 
membranous ERa have also been associated with oestrogen-induced MAPK 
activation in MCF-7 cells (Zivadinovic and Watson, 2005). In addition, in vitro 
evidence has also suggested that resistance to Tamoxifen-induced apoptosis is 
associated with a direct interaction between HER2 and a cell membrane ER (Chung et 
al., 2002). If present in vivo, these interactions could provide a mechanism for a 
positive feedback loop, vdiere following activation o f the HER2-ERa axis at the cell 
surface, activation o f downstream signalling proteins such as MAPK and Akt initiate 
phosphorylation of the ERa at the nucleus (Figure 8). Interesting, recent evidence has 
also suggested that HER2 overexpression in ERa positive breast cancer cells 
promoted nucleus to cytoplasm relocalisation o f ERa so demonstrating further
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evidence for a interaction between the HER family and ERa cellular location (Yang et 
al., 2004).
Figure 8
ER at the membrane may directly signal via interaction/crosstalk with HERl 
(Razandi et al., 2003b).
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1.8 Statement of Aims
A retrospective clinical follow up study has been performed on archival formalin - 
fixed paraffin embedded tissues, to further examine the relationship between the well 
demonstrated ERa-HER pathway crosstalk and Tamoxifen resistance. Tissue blocks 
from patients who had ERa positive cancers and who were treated with Tamoxifen 
have been analysed and the results correlated with clinical progression of these 
patients on Tamoxifen (i.e. Tamoxifen resistant disease).
The initial hypothesis under test is that the cases positive for H ERl-3 (but not HER4) 
will exhibit de novo resistance to Tamoxifen treatment reflected by shortened time to 
relapse on Tamoxifen treatment. We also postulate that this may occur following 
cross talk between the HER family and the ERa and have therefore examined 
evidence of ERa activation in these patients by analysing the phosphorylation status. 
In addition, as discussed earlier, recent trial results (Coombes et al., 2004a; Dowsett,
2003) demonstrate that PR status can determine who responds to early or to delayed 
treatment with aromatase inhibitors. Given the known inverse relationship between 
PR expression and HER2 expression (Marsigliante et a l, 1993; Quenel et a l, 1995) 
we therefore also postulate that both H ER l-3 and PR expression are time dependent 
predictors of Tamoxifen resistance (as would be predicted if these were de novo 
resistance mechanisms).
There is a need to address some of the problems we have identified previously when 
considering this relationship between the HER family and Tamoxifen resistance.
1. Much of the previous work has looked at the individual HER receptors in 
isolation. However, as explained, many of these receptors are co-expressed and 
certainly in the case of the potent HER2-HER3 heterodimer rely on each other for
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signal transduction. Thus we will determine H ERl-4 status in these tumours and 
identify the role that coexpression of receptors may play in determining 
Tamoxifen resistance.
2. The numbers involved has limited many previous studies. The small percentage of 
patients who are both ERa and HER positive will always limit the power of a 
study. We will use tissue micro array technology to increase the numbers of 
tumour samples we can analyse. This involves removing cores from pre-existing 
paraffin embedded blocks and reembedding them in an arrayed master block. 
Subsequent analysis of hundreds of specimens on only a few slides is therefore 
possible. There is also the additional advantage that all specimens are analysed 
under identical conditions. This technique has been validated in breast cancer 
(Torhorst et al., 2001) and will be discussed in more detail in the methods section.
3. During the course of undertaking this work, increasing evidence has come to light 
with regard to the cellular localisation of both the ERa and HER receptors. As 
discussed earlier ERa has been shown to act at the membrane (Razandi et a l, 
2002; Razandi et al., 2000) and there has also been studies reporting the existence 
of various members of the HER family at the nucleus (Razandi et a l, 2003a; Lin 
et a l, 2001; Ni et a l, 2001; Offterdinger et a l, 2002). The exact function of the 
receptors at these sites is not clear. Wliilst scoring the TMAs for 
presence/intensity of receptor positivity, it will be important to also play close 
attention to the cellular location of any staining.
4. Although the many studies have demonstrated amplification or overexpression of 
the HER receptors in relation to Tamoxifen resistance, we do not know if  these 
extra receptors are in fact activated. One way of demonstrating activation is by 
examination of the phosphorylation status of the receptors. Indeed phosphoiylated
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HER (determined using immunohistochemistry) was demonstrated in only 12% of 
HER2 positive patients in a recent study (Thor et al., 2000). They suggested that 
phospho"HER2 status provided improved prognostic information compared to 
HER status alone. We will therefore determine phosphorylated HER2 status in 
this study.
5. As discussed earlier one possible explanation for the conflicting reports on HER4 
and its association with survival may be that the results are antibody dependent. 
We have therefore chosen to compare the staining patterns of widely used 
antibodies in standardised conditions which are known to target either the 
intracellular (HFRl) or extracellular (H4.77.16) domains of HER4.
Thus a summary of the aims would be to
1. identify the H ERl-4 status of the tumours by analysis of protein expression
2. identify activation of ERa by assaying the phosphorylation of ER at the 2 key
sites discussed earlier using antibodies to SER 118 and SER 167
3. identify if PR status correlates with HER family positivity
4. investigate the activation of HER2 by assaying its phosphorylation status
These results would then be analysed to:
1. identify any relationship between HER 1 -4 and ERa phosphorylation
2. establish if activation of ERa by H ER l-4 is associated with resistance to
tamoxifen
3. identify any correlation between PR status and Tamoxifen resistance
4. determine if PR and/or HER family associated Tamoxifen resistance is time 
dependent.
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Future Implications
This department is currently constructing a TMA bank from cases involved in the 
TEAM trial. Markers identified as being significant from this work will be used in the 
prospective translational research arm of the trial.
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Chapter 2 Methods
2.1 Patient Seleetion
2.1.1 Ethical clearance
Ethical clearance was obtained from the Glasgow Royal Infirmary LREC committee 
(LREC 02SG007).
2.1.2 Patient Database
Details of sequentially diagnosed breast cancer patients, suitable for surgical excision, 
from years 1980 -1999 had been kept in a registered database kept within the 
University Department of Surgery. These patients had surgery and subsequent 
adjuvant therapy according to protocols at the time of diagnosis. Patients who had 
neoadjuvant treatment in terms of endocrine treatment, chemotherapy and 
radiotherapy prior to their surgeiy were also included in the database. The total 
number of patients in the database is 1116. Patient follow-up details have been 
entered prospectively since diagnosis. These entries include information on 
attendances, recurrence and metastasis details, date and cause of death and adjuvant 
therapy details (including tamoxifen treatment duration).
From this database, patients were selected who had been treated with adjuvant 
Tamoxifen therapy and who were either known to be ER positive or who did not have 
a record of ER status being tested. Patients with an unknown ER status were included 
to increase the numbers available for analysis, on the basis that all patients in the 
study would have their ER status re-tested. The number of Tamoxifen treated ER 
positive or ER unknown tumours was 685.
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1.3 Patient Exclusion
From this group of 685 patients, further exclusions were made on the following basis:
1. If  their follow up and full Tamoxifen history was not complete in terms of 
details of any relapse or duration of Tamoxifen ti eatment (n=52).
2. If the tumour blocks from pathology were not available or deemed unsuitable 
by the pathologist (B Dunne) because of limited tissue availability which may 
have compromised further diagnostic testing (n=177).
456 patients were therefore eligible for the study. 75 of these patients were ER 
nonspecified, with the remainder having being tested positive for ER by either ligand 
binding (130) or immunohistochemistry (251). No details about the methodology of 
these diagnostic tests over the years was available, and in the majority of cases it was 
only documented if the patient was ER positive or negative with no details on the 
values of ligand binding assay value or IHC score.
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2.2 TMA construction
2.2.1 TMA Technology
One of the key objectives of this study was to utilise a method by which many tissue 
samples could be tested for multiple antibodies in a limited amount of time. Tissue 
microarray technology has been increasingly used as a way of achieving this objective 
since it was developed by Kononen et al in 1998 (Kononen et al., 1998). Since then 
various studies have published work validating TMA use in both breast cancer and 
other tissues (Camp et al., 2000; Hoos and Cordon-Cardo, 2001; Torhorst et al., 
2001). The technique involves removing a representative core of tissue (0.6mm 
diameter) from the tumour block and inserting it into a recipient block along with 
cores from other donor blocks. The recipient block can then be sectioned and used for 
routine analysis in the same way as standard sections. Up to 300 individual tumour 
cores may be placed into a single recipient block thus enabling multiple tumour 
analysis in one IHC staining run.
The advantages of using micro array technology include bring able to perform high 
speed analysis, whilst minimising damage done to donor blocks so presemng 
valuable tissue for further research or diagnostic needs. In addition it enables 
standardisation of testing, with direct comparison of staining intensities between 
specimens so improving the subjective interpretation of results.
However there are some problems associated with this technique.
2.2.1.1 Missing samples/Loss rate
Cores within a TMA section may be damaged or lost during sectioning, or the core 
may not contain identifiable tumour. Core loss duiing sectioning and staining is a
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common problem with microarrays and ranges from 10% to more than 30% 
(Bubendorf et al., 1999; Hoos and Cordon-Cardo, 2001; Schraml et al., 1999; 
Torhorst et al., 2001). Sectioning loss can be minimised when performed by a suitably 
trained and experienced technician, and by attempting to array uniformly long cores 
for each specimen. The chance of obtaining identifiable tumour in the core can be 
maximised by using a trained pathologist to identify representative tumour areas.
The impact of lost cases can be minimised by increasing the number of cores taken 
per specimen. Parallel TMAs are therefore constructed for each series of original 
specimens. Torhorst et al (Torhorst et al., 2001) correlated the results from standard 
tissue sections with the results from 4 independent TMAs. They found that the 
fraction of interpretable tumours was 86-93% if 2 cores were available, 92-96% if 3 
cores available and 94-96% if all 4 cores available depending on antibody tested (PR, 
ER andp53).
2.2.1.2 Heterogeneity
Breast cancers are heterogeneous at both a moiphological and genetic level (Osborne, 
1985; Symmans et al., 1995). One potential drawback with TMA technology is that 
the 0.6mm biopsies taken from a tumour block will not be representative of the whole 
tissue specimen because of tumour heterogeneity. It has been suggested that optimum 
number of core-cut biopsies required to ensure an accurate histological diagnosis and 
grading of a tumour is 4 (Mcllhenny et al., 2002). However this study was based on 
free hand core techniques and 8% of the cores had no discernable histological features 
at all. Tohorst et al (Torhorst et al., 2001) reported that the fraction of tumours with 
heterogeneous findings was 9% for ER, 29% for PR and 11% for p53. For PR they 
required 3 samples of each tumour to achieve the same levels of positivity as large
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section analysis. However it must be remembered that a tumour block itself often 
represents a small fraction of the actual tumour. Camp et al (Camp et al., 2000) 
compared the results of expression of HER2, ER and PR in up to 10 cores per 
specimen with the results from standard tissue sections. They reported that results 
combining 2 cores demonstrated over 95% concordance between these two methods, 
and that the addition of a 3^  ^core increased concordance to over 97%.
Hoos et al (Hoos and Cordon-Cardo, 2001) analysed results found when looking at a 
more complex phenotype of expression of retinoblastoma (RB) protein. They 
demonstrated that using just 2 cores per specimen required some cases to be excluded 
from analysis is instances where there were contradictory results. However the 
addition of a 3“* core to the analysis improved concordance rates to 91%.
Based on the above results, we decided to minimise the effects of core loss and tissue 
heterogeneity by constructing the TMAs in triplicate. However more recent 
publications have suggested that at least 4 cores are required, especially for markers 
with a heterogeneous staining pattern such as PR (Sapino et al., 2006).
2.2.2 Technique
This department has been using TMA technology for some time in IHC and FISH 
analysis of breast, ovaiian and prostate tissue. We are currently involved in the 
construction of TMAs for the TEAM and NEAT (National Epirubicin Adjuvant Trial) 
trials. The TMAs were constructed for this study by myself under guidance from 
pathology MLS Os working within the department.
Formalin fixed paraffin embedded tissue bocks, prepared after surgical excision of the 
tumours, were obtained from the department of pathology. A tissue section from each 
block was stained using haematoxylin and eosin (H&E) to identify areas of tumour.
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Representative areas on the H&E were identified by a pathologist (Barbara Dunne) 
and marked on the slide. As discussed earlier this is essential as it ensures the core 
taken contains representative tumour cells.
Prior to removing the cores, 5 x 3pM sections were cut from each pathology block by 
a MLSO in the lab. These sections have been stored and may be used in the case of 
any missing samples from the TMA slides or to validate the TMAs in any cases where 
there are doubts about the heterogeneity of tissue staining for a particular antibody. 
Subsequently 3 * 0.6mm cores of tissue were removed from each block at the area 
marked by BD using a tissue arrayer (Beecher instrument). This precision instrument 
uses 2 separate core needles for punching the donor and recipient blocks, together 
with a precise co-ordinate system to place and locate the tissue samples in the array. 
These cores of tissue were then transformed to 3 recipient blocks (80-120 cores per 
block) to form triplicate tissue arrays. In total we constructed 5 different arrays each 
in triplicate (total 15 donor blocks).
2.2,3 TMA Layout
The cores were placed at 1 mm intervals, with regular larger gaps as to ensure ease of 
identification of core position during analysis (Figure 9).
row normal tissues
1 2 3 5 6 7 8 9 11 12 13 14 15
Figure 9
Illustration o f  typical core placement layout in TMA.
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2.2.4 Control Tissues
Cores were taken from 10 blocks containing samples of normal tissue (sourced from 
USA commercial). These nomial tissues consisted of skeletal muscle, smooth muscle, 
normal breast, lung, placenta, prostate, tonsil, lymph node, skin and testes. A core 
from each of these was placed in order, in a row, above the tumour cores in each of 
the 15 donor blocks. This provides the basis of controls for each of the antibodies, 
which have known staining patterns in normal tissues. This row of normal tissues 
also provided a mechanism for correct orientation of the TMA section after 
sectioning.
The completed tissue array blocks were heated at 37° for 10 minutes to ensure the 
tissue cores and paraffin stick together. Serial 3pM sections were then cut by a MLSO 
from the TMAs using silanised slides to improve section contact with the slide during 
high temperatures used in some antigen retrieval protocols.
Given the extremely valuable natuie of these TMAs in terms of a future research 
resource we took care to establish clear criteria for the number and timing of any 
TMA sections cut. Cutting too few sections would result in wastage (re-aligning and 
facing blocks to cut into them) whilst cutting too many may result in tissue oxidation 
of unused sections over time.
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2.3 Immunohistochemistry
Immimohistochemisüy involves using an antibody to link a cellular antigen 
specifically to a stain that can be more readily seen with a microscope. Advantages of 
IHC include the ability to detect location of staining as well as providing a semi 
quantitative assessment of intensity. Problems however can occur in relation to 
specificity of the antibody as well as the need to expose antigenic sites to the 
antibody, particularly in formalin fixed tissues.
The 10 antibodies were chosen to achieve the aims for this study. These were 
antibodies against ER, PR, EGFR (HERl), HER2, HER3, HER4 (2 antibodies), 
phosphoiylated HER2 and phosphoiylated ER at 2 sites (serine 118 and serine 167). 
A summaiy of the antibodies used is attached in Appendix I.
2.3.1 Antibody Protocols: General principles
During the work up of the antibodies I followed a set of general principles described 
below which were subsequently tailored to each antibody as described in detail later. 
Both breast cancer whole sections and sections from a small practice TMA were used 
during the work up of all antibodies (as well as the relevant control slides).
A. Dewax, rehydmiion
Prior to any immunohistochemical staining using formalin fixed, paraffin embedded 
tissue, sections have dewaxed and rehydrated. Paraffin must be removed from the 
tissue to allow the water-based buffers and antibodies to penetrate.
For all antibody protocols this was done using the following regime:
1. Dewax in xylene (Fishers chemicals) 2* 4minutes
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2. Rehydrate in graduated alcohols;
• 100% alcohol 2*4minutes
• 90% alcohol 2minutes
• 70% alcohol 2 minutes
3. Rinse in water
B. Block o f endogenous peroxidase activity
Breast tissue is known to contain endogenous peroxidase. To minimise background 
staining from this, sections were treated with hydrogen peroxidase (VWR 
International Ltd; supplied at concentration ~ 30%), which is known to iixeversibly 
inactivate endogenous peroxidase. This was done either before or after antigen 
retrieval at a concentration of either 0.3% or 1% for either 10 or 20 minutes 
depending on the protocol determined for each antibody.
C. Antigen retrieval
To facilitate the antibody - antigens reactions in fixed tissue, it may be necessary to 
unmask or “retrieve” the antigens through pretreatment of the specimens. Antigen 
retrieval has been shown to increase reactivity of the majority of antigens in tissues. 
This was done by one of three methods under routine use in the lab, depending on the 
antibody used. These methods were:
1. Pressure microwave treatment in Tris EDTA buffer (0.37g sodium EDTA (BDH 
Laboratory Supplies) and 0.55g Tris base (Sigma) made up to 1 Litre with dH2 0 ). 
Microwave irradiation of formalin-fixed, paraffin-embedded specimens in buffer has 
been found to markedly enhance the retrieval of antigens. During this procedure the 
energy provided helps break some of the bonds formed during fixation, thus 
increasing the intensity of reactions.
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2. Boiling (in calibrated water bath set at 96°) in lOmmoI/L citrate buffer (we used 
1:10 Epitope Retrieval solution taken from DAKO Herceptest kit) for 20minutes.
3. Trypsinisation. Sections are incubated in 0.1% trypsin (Sigma) (dissolved in 0.1% 
calcium chloride (Sigma) solution preheated in a 37° waterbath) for 10 minutes. The 
conditions of concentration, time and temperature must be tightly conti'olled, so that 
the enzymes can break some of the bonds formed during fixation, uncovering 
antigenic sites, but the antigen should not be digested completely.
The choice of antigen retrieval method will be discussed later for individual 
antibodies.
D. Blocking non-specific background staining
Any non-specific background staining was blocked using one of 2 methods depending 
on the protocol. This was done by either:
1. Serum Free block (0.25% casein in PBS, containing carrier protein and 15mM 
sodium azide; DAKO) for 10 minutes
2. Normal horse serum (Vector) at concentration of 15pl/ml for 15 minutes 
Following incubation with blocking agent the solution was tapped off and the sections 
were blotted.
E. Blocking o f  Endogenous Biotin
Breast tissue is known to contain endogenous biotin. To minimise background 
staining, most of the protocols required treatment with an Avidin/Biotin Blocking 
agent (Vector) following the incubation with the horse serum or serum-free block. 
This was done by:
1. Incubation with Avidin D solution 15 minutes
2. 5 minute wash in TBS buffer
3. Incubate with Biotin solution for 15 minutes
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4. 5 minute was in TBS buffer
F. Incubation with Primary antibody
Sections were incubated with the primary antibodies at optimum concentrations and 
conditions determined for the individual antibodies (as described later). Antibodies 
(including the negative control antibodies) were always diluted in a tris-HCL buffer 
containing carrier protein and 0.015M sodium azide (DAKO). A slide from each run 
was always incubated with an isotype matched control antibody whilst working up the 
antibodies and in the final runs to ensure no false positive staining. Slides were 
washed twice in TBS buffer for 5 minutes following incubation.
G. Visualisation Methods
I used the DAKO LSAB+ Kit HRP, which utilises a refined avidin-biotin technique in 
which a biotinylated secondaiy antibody reacts with several peroxidase-conjugated 
streptavidin molecules. Slides were washed in TBS buffer between and after 
incubations with the link antibody and Strepavidin peroxidase solutions.
Detection was then completed with incubation with a 3,3’diaminobenzidine (DAB) 
solution (Vector Laboratories) for 2-10 minutes. The DAB solution was washed off in 
running water for 10 minutes.
H. Counterstaining, Dehydration and Mounting
The sections were counterstained, and then dehydrated using the following method.
• Haemoxylin 1 minute followed by rinse in mnning H2O
• Blue with Scotts tap water substitute (about 30 seconds) followed by rinse in
running H2O
• 70% alcohol 1 minute
• 90% alcohol 1 minute
• 100% alcohol 2*1 minute
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• xylene 2*1 minute
• slides were then mounted in DPX
Note: TBS buffer solution
Tris base saline buffer was made in the laboratory at a 1:10 dilution of a solution 
made by dissolving 60g Tris base and 87.6g NaCL perlL (IH2O (pH to 7.5).
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2.3.2 IHC protocol for ER
(Dako: clone 1D5 monoclonal IgGl mouse antibody)
To stain for ER I used a DAKO ER antibody used routinely in the diagnostic setting 
in our pathology department. The protocol used is given below.
*Make up Tris EDTA buffer +start warming solution while rehydrating
A) Dewax and réhydraté 
Dewax in xylene 2*4 min
Rehydrate in 100% alcohol 2*4 min 
90% alcohol 2min
70% alcohol 2min
rinse in water
Incubate sections in 0.3% H2O2 for 20 mins (8ml H2O2 in 400ml d H2O) 
rinse in water
B) Antigen retrieval
• make up Tris EDTA buffer (pH8)
• 0.37g sodium EDTA
.  0.55g Tris
• make up to 1 Litre with (IH2O
• microwave full power 14 min to warm solution
• add slides and lid and microwave on full power for 2 min to bring up pressure 
(lift yellow cap)
• microwave for 5 min under pressure
• remove weight to allow steam to escape
• cool for 20min
• wash running water
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C) Staining
• DAKO pen to ring sections
• Incubate in blocking solution for 15 min (15 p horse serum per ml TBS)
• Blot serum from sections
• Incubate in primary antibody at room temp for 30min (1:50 in antibody 
dilutent)
• Wash TBS 5min
• Incubate in secondaiy antibody (DAKO yellow) for 15 min at room temp
• Wash TBS 5min
• Incubate in Streptavidin HRP (DAKO red) for 15 min at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5ml d H2O: add 2 drops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix) 30sec
• Wash running water lOmin
D) Counterstain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
• xylene 2* Imin
• mount in DPX
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2.3.3 EHC protocol for PR
The TMA sections were given to the department of pathology and processed as part of 
a diagnostic run for PR staining.
2.3.4 IHC protocol for EGFR 
(Mouse monoclonal IgGl Zymed 28-0005 clone 31G7)
We used a mouse anti-EGFR antibody whose use on breast cancer sections was first 
described in 1984 (Gusterson et al., 1984). It is a Zymed product; clone 31G7, 
monoclonal IgGl antibody. It has subsequently been used in a large neoadjuvant 
clinical trial (Ellis et al., 2001). We also have experience in using this antibody in the 
laboratoiy in analysing overexpression of EGFR in prostate cancer, and this protocol 
was followed without modification as described below.
*Put 80ml 0.1% calcium chloride solution in 37° water bath
A) Dewax and rehydrate
• Dewax in xylene 2*4 min
• Rehydrate in 100% alcohol 2*4 min
• 90% alcohol 2min
• 70% alcohol 2min
• rinse in water
• Incubate sections in 0.3% H2O2 for 20 mins (4ml H2 O2 in 400ml d H2O) on 
stirrer
• rinse in water
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B) Antigen retrieval
• Make up 0.1% trypsin in preheated 0.1% calcium chloride and allow to 
dissolve: (0.08g)
• Incubate slides in trypsin for 1 Omin in 37° water bath
• Wash in running water
• Transfer slides to a staining dish with water (slides can be stored like this)
C) Staining
• DAKO pen to ring sections
• Incubate in blocking solution for 20min (15pi horse serum per ml TBS)
• Blot serum from sections
• Incubate in primary antibody for 1 hour in humidified chamber at 25° (1:50 in 
DAKO antibody dilutent)
• Wash TBS 5min
• Incubate in secondary antibody (DAKO yellow) for 30 min at room temp
• Wash TBS 5min
• Incubate in Streptavidin HRP (DAKO red) for 60min at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5ml d HgO: add 2 drops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
D) Counterstain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
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E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
• xylene 2* Imin
• mount in DPX
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2.3.5 IHC protocol for HER2
(Dako HercepTest^^* Immunogen is the synthetic C-terminal fragment 
(intracytoplasmic part) of the HER2 protein)
This laboratory is an approved national testing centre for HER2. My slides were 
included in a diagnostic run using the DakoCytomation Autostainer. We also plan to 
use these slides in a HER2 FISH but these results will not be available for report in 
this thesis.
A) Dewax and rehydrate
• Dewax the slides: 2 x 5  mins in Xylene
• Rehydrate: 2 x 3 mins 100% alcohol
• 3 mins 90% alcohol.
• Rinse in Water.
• Rinse in water.
B) Epitope Retrieval
• 40 mins at 96 °C in heated water bath.
• Cool for 20 mins.
• Transfer in to wash buffer for 5 mins
C) Staining
• R n g  sections with DAKO pen to create a barrier
• Incubate in peroxidase blocking reagent for 5 mins.
• R nse in water.
• Incubate in primary antibody in humidified chamber for 30 mins.
• Wash 5 mins in wash buffer
• Incubate in visualization reagent at room temp for 30 mins
• Wash 5 mins in wash buffer.
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• Make DAB substrate. To 1 ml DAB substrate add 1 drop DAB chromogen
• Incubate sections with substrate until colour develops (10 mins)
• Wash in water.
D) Counterstam
• Stain in haematoxylin for 3 mins.
• Rinse in running tap water
• Blue with Scotts tap water substitute
• Rinse in running tap water
E) Dehydrate and mount
• 1 min 70% alcohol
• 1 min 90% alcohol
• 2 x 1  min 100% alcohol
• 2 x 1  min xylene
• mount in DPX
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2.3.6 IHC protocol for HER4
As discussed previously we wished to compare the staining results of 2 HER4 
antibodies which target either intra -  or extracellular domains. Monoclonal IgG2b 
mouse antibody HFRl was first used by Srinivasan et al (Srinivasan et a l, 1998) in 
1998 to determine the expression of HER4 in formalin fixed paraffin embedded 
noimal tissues and cancers. This group demonstrated the ability of this antibody to 
recognise HER4 by immunoprécipitation, western blotting and immunostaining of 
cytocentrifuge preparations of NH3T3 cells transfected with HER4. There was no 
crossreactivity with EGFR using A431 cell lysates or with HER3 or HER4 using 
lysates from SKBR3 or 293/HER3 cells. We wished to compare the staining patterns 
of this antibody to those of a second monoclonal IgGl antibody clone H4.77.16 also 
supplied by Neomarkers. Our laboratoiy has previous experience in using this 
antibody in frozen breast cancer samples (Witton et a l, 2003). The HFR-1 antibody is 
raised against an intracellular epitope aal 249-1264 whilst the H4.77.16 antibody is 
raised against an extracellular fragment. Therefore HFRl is thus able to recognise 
both the intact receptor and the cleaved ICD as it traffics through the cell. However 
the H4.77.16 clone will detect the full length receptor not the cleaved ICD.
2.3.6.I HFRl
(Mouse monoclonal Ab Clone HFR-I#MS 637-Po)
The datasheet for this product suggested that the antibody should be used at a dilution 
of between 1:40 to 1:20 from the initial concentration of 200pg/ml with no antigen 
retrieval required. Breast cancer sections were used in the work up of this antibody 
together with skeletal muscle slides provided by Neomarkers used as positive control 
slides. Antibody concentrations from 1:10 to 1:100 incubated over periods of between
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30 minutes and 2 hours were tried, with the optimum antibody concenti'ation found to 
be at a 1:50 dilution (i.e. 4pg/ml) for 1 hour. Initially there was some residual mild 
background staining seen on the negative control slides, however this was eliminated 
when the hydrogen peroxide concentration was increased to 1% for 20 minutes and 
serum free block (DAKO) was used instead of horse serum as a blocking agent. This 
method provided the optimum range of staining intensity with minimal background 
staining and clear negative control slides.
A) Dewax and rehydrate 
Dewax in xylene 2*4 min
Rehydrate in 100% alcohol 2*4 min 
90% alcohol 2min
70% alcohol 2min
rinse in water
Incubate sections in 1% H2O2 for 20 mins (13.3ml H2O2 in 400ml d H2O) 
rinse in water
B) No Antigen retrieval
C) Staining
• DAKO pen to ring sections
• Incubate in serum free blocking solution for I Omin
• Blot serum from sections
• Avidin Biotin Block (Avidin 15min / TBS 5min / Biotin 15 min / TBS 5min)
• Incubate in primary antibody at room temp for 1 hoiu' (1:50 in antibody
dilutent)
• Wash TBS 5min
• Incubate in secondary antibody (DAKO yellow) for 30 min at room temp
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• Wash TBS 5min
• Incubate in Streptavidin HRP (DAKO red) for 60min at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5mi d H2O: add 2 drops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
D) Counterstain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
• xylene 2* Imin
• mount in DPX
23.6.2 H4.77.16
(Mouse monoclonal Ab, IgGlclone H4.77.16 #MS-270-PABX)
The datasheet for this antibody did not provide any guidance for its use in IHC and 
the only other published work using this antibody was for immunoprécipitation and 
flow cytometry (Tang et al., 1999; Witton et a l, 2003) . However it had been used 
within our lab on frozen tissue sections (Witton et a l, 2003). On frozen tissue the 
antibody was used a concentration of 2|o,g/ml overnight at 4°. No antigen retrieval had
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been used and biotinylated secondary antibodies with horseradish peroxidase 
streptavidin-biotin complex and DAB were used for antibody detection. The initial 
work up of this antibody attempted to replicate this method following dewaxing and 
rehydration of the cut sections. However no staining was detected using this method. 
Therefore a modification of the protocol used with the HFRl antibody was tried. This 
method using an antibody dilution 1:20 (50|ug/ml) for 2 hours provided optimum 
range of staining intensity with minimal background staining and clear negative 
control slides.
A) DeM>ax and rehydrate 
Dewax in xylene 2*4 min
Rehydrate in 100% alcohol 2*4 min
90% alcohol 2min
70% alcohol 2min
rinse in water
Incubate sections in 1% H2O2 for 20 mins (13.3ml H2O2 in 400ml d H2O) 
rinse in water
B) No Antigen retrieval
C) Staining
• DAKO pen to ring sections
• Incubate in serum free blocking solution for lOmin
• Blot serum from sections
• Avidin Biotin Block (Avidin 15min / TBS 5min / Biotin 15 min / TBS 5min)
• Incubate in primaiy antibody at room temp for 2 HOURS (1:20 in antibody
dilutent)
• Wash TBS 5min
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• Incubate in secondary antibody (DAKO yellow) for 30 min at room temp
• Wash TBS 5min
• Incubate in Streptavidin HRP (DAKO red) for 6Omin at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5ml d H%0: add 2 drops
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
D) Coimterstain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
xylene 2* Imin*
mount in DPX
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2.3.7 IHC protocol for HER3
(Mouse monoclonal, IgGl, clone H3.105.5, #MS-303-PABX)
We used a monoclonal IgGl antibody clone H3.105.5 supplied by Neomarkers. This 
antibody is raised against the extracellular domain of recombinant human HER3 
oncoprotein Our laboratory has previous experience in using this antibody in frozen 
breast cancer samples (Witton et al., 2003). The antibody has previously been tested, 
within the laboratory, using an immunohistochemical immunoperoxidase technique 
for its ability to detect HER3 in frozen sections of pellets of cells transfected with c- 
erbB-3 c-DNA and expressing high levels of protein. Both antibodies labelled these 
cells strongly but not the untransfected parent line (data unpublished).
The datasheet for this product did not provide any guidance for its use in IHC and the 
only published work using the antibody for immunoprécipitation (Chen et al., 1996). 
However it had been used within our lab to determine protein expression on frozen 
tissue sections. On frozen tissue the antibody had been used at a concentration of 
2pg/ml overnight at 4°. No antigen retrieval was used and biotinylated secondary 
antibodies, horseradish peroxidase streptavidin-biotin complex and DAB were used 
for antibody detection. My initial work up of this antibody attempted to replicate this 
method following dewaxing and rehydration of the cut sections. However no staining 
was detected using this method. Therefore a modification of the protocol used for the 
HER4 antibodies was tiled with no antigen retrieval and room temperature 
incubations. This method demonstrated some staining. The protocol was then run at 
antibody concentrations between 1:10 and 1:100 dilutions for between 30 minutes and 
2 hours. These titrations demonstrated that the antibody dilution 1:20 (50pg/ml) for 2 
hours provided the optimum range of staining intensity with minimal background 
staining and clear negative control slides.
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A) Dewax and rehydrate
• Dewax in xylene 2*4 min
• Rehydrate in 100% alcohol 2*4 min
• 90% alcohol 2min
• 70% alcohol 2min
• rinse in water
• Incubate sections in 1% H2O2 for 20 mins (13.3ml H2O2 in 400ml d H2O)
• rinse in water
B) No Antigen retrieval
C) Staining 
DAKO pen to ring sections
Incubate in serum free blocking solution for lOmin 
Blot serum from sections
Avidin Biotin Block (Avidin 15min / TBS 5min / Biotin 15 min / TBS 5min)
Incubate in primary antibody at room temp for 2 HOURS (1:20 in antibody
dilutent)
Wash TBS 5min
Incubate in secondaiy antibody (DAKO yellow) for 30 min at room temp 
Wash TBS 5min
Incubate in Streptavidin HRP (DAKO red) for 6Omin at room temp 
Wash TBS 5min
Incubate in DAB substrate until colour develops (5ml d H2O: add 2 drops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
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D) Counterstam
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
• xylene 2* Imin
• mount in DPX
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2.3.8 IHC protocol for phospho specific HER2 (pHER2)
(Mouse monoclonal Ab IgGl, Ab-18 (clone PN2A), #1072 Neomarkers)
HER2 has at least 4 tyrosine autophosphorylation sites including Tyrl023 and 
Tyrl248 on the C-terminal (Hazan et a l, 1990). Antibodies against the Tyrl248 site 
have been developed (DiGiovanna and Stem, 1995; Epstein et a l, 1992) by raising 
antisera against the tyrosine-phosphorylated c-terminal (residues 1243-1255) HER2 
peptide sequence and the resultant clone PN2A is commercially available from 
Neomai'kers. Specificity of this clone was demonstrated, by its’ developers, by its 
ability in immunoblotting to recognise p i85 in a tyrosine-phosphorylation dependent 
manner without recognising the closely related phosphoiylated EGFR or the highly 
homologous COOH terminus of HER4 (DiGiovanna and Stem, 1995; Bangalore et 
al, 1992).
We used the Neo markers PN2A clone (monoclonal IgGl). The datasheet for this 
product suggested antigen retrieval was optimised by boiling sections in lOmM citrate 
buffer followed by incubation of the antibody diluted to between 1:10 and 1:20 times 
the original concentration of 200pg/ml for 2 hours at room temperature. Positive 
control slides supplied by Neomarkers and sections from paraffin embedded SKBR-3 
cells (known to express phosphoiylated HER2 (DiGiovanna and Stem, 1995) were 
used a positive controls to work up antibody.
Antibody retrieval was peifonned by boiling (in calibrated water bath set at 96°) the 
sections in lOmmol/L citrate buffer (1:10 Epitope Retrieval solution taken from 
DAKO Herceptest kit) for 20minutes.
Antibody dilution titrations were peifoimed for 1:100, 1:50, 1:20 and 1:10 
concentrations. I also compared the results of incubating the antibody overnight for 4° 
to incubation at room temperature from between 2 hour and 8 hour durations.
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Incubation with the antibody at 1:10 concentration for 6 hours at room temperature 
provided the optimum results in terms of range of intensity staining combined with 
minimal background staining and clear control slides.
A) Dewax and rehydrate
• De wax in xylene 2*4 min
• Rehydrate in 100% alcohol 2*4 min
• 90% alcohol 2min
• 70% alcohol 2min
• rinse in water
• Incubate sections in 1% H2O2 for 10 mins (13.3ml H2O2 in 400ml d H2O)
• Rinse in water
B) Antigen retrieval
• 1:10 HER2 antigen retrieval solution used
• 20min 96°
• 20min cool
• rinse in water
C) Staining
• DAKO pen to ring sections
• Incubate in serum free blocking solution (DAKO) for lOmin
• Blot serum from sections
• Avidin Biotin Block (Avidin 15min / TBS 5min / Biotin 15 min / TBS 5min)
• Incubate in primaiy antibody at room temperature for 6° (1:10 in antibody
dilutent)
• Wash TBS 5min
• Incubate in secondary antibody (DAKO yellow) for 30 min at room temp
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• Wash TBS 5min
• Incubate in Streptavidin HRP (DAKO red) for 60min at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5ml d H2O: add 2 drops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
D) Counterstain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2* 1 min
• xylene 2* Imin
• mount in DPX
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2.3.9 IHC protocol for Phospho specific ER
The oestrogen receptor has multiple phosphoiylation sites, which modulate the 
function of the receptor as discussed previously. We wished to concentrate on the 
phosphorylation sites of Serine 118 (the putative target of the MAPK pathways) and 
Serine 167 (the putative target of the Akt pathway). Antibodies to each of these sites 
aie commercially available. There is no published literature regarding either of these 
antibodies.
2.3.9.1 Phospho ERa Serine 118
(Mouse monoclonal, IgG2b 16 J4 antibody #2511 cell signalling)
The Phospho-oestrogen receptor (serl 18) 16J4 antibody was purchased from Cell 
signalling. It is a 65.5 kDa monoclonal antibody, (isotype IgG2b) produced by 
immunising mice with a synthetic phosphopeptide coixesponding to residues 
surrounding Serl 18. Product literature for the antibody demonstrates its ability to 
detect ER only when phosphorylated at Serl 18, with no cross reactivity with ER(3. 
Breast cancer sections were used in the work up of this antibody. The datasheet for 
this antibody suggested heating the sections in lOmM sodium citrate buffer for 10 
minutes. It suggested overnight incubation at 4° at 1:50 dilution (in blocking 
solution). However using this method, there was some slight background staining on 
some sections treated with an isotype matched control antibody. By changing the 
antigen retrieval time to 20 minutes (as per Herceptest), diluting the antibody in 
DAKO antibody dilutent and using protein free block instead of horse serum, this 
background was eliminated. Using this method at 1:50 the staining pattern was 
generally strong throughout the majority of positive sections, therefore antibody 
titration was performed using dilutions from 1:50 to 1:500. The optimum
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concentration in terms of range of intensity staining and minimal background staining 
was found to be 1:300.
A) Dewax and rehydrate
• Dewax in xylene 2*4 min
• Rehydrate in 100% alcohol 2*4 min
• 90% alcohol 2min
• 70% alcohol 2min
• rinse in water
B) Antigen retrieval
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?£
• 1:10 HER2 Ag retrieval sol used
'*
• 20min 96°
• 20min cool
• rinse in water
• Incubate sections in 1% H2O2 for 10 mins (13.3ml H 202 in 400ml d H2O)
C) Staining
• DAKO pen to ring sections
• Incubate in serum free blocking solution for 1 Omin
• Blot serum from sections
• Avidin Biotin Block (Avidin 15min / TBS 5min / Biotin 15 min / TBS 5min)
• Incubate in primary antibody at 4° overnight (1:300 in antibody dilutent)
• Wash TBS 5min
• Incubate in secondaiy antibody (DAKO yellow) for 30 min at room temp
• Wash TBS 5min
• Incubate in Streptavidin HRP (DAKO red) for 60min at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5ml d H2O; add 2 di'ops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
D) Counterstain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
• xylene 2* Imin
• mount in DPX
2.3.9.2 Phospho ERa Serine 167 
(Rabbit polyclonal Ab, #2514 cell signalling)
The phospho-oestrogen receptor (serl67) polyclonal antibody (Cell Signalling) was 
produced by immunising rabbits with a synthetic phospho-serl67 peptide 
corresponding to residues surrounding Seri 67 of human ER. Product literature for this 
antibody states that the antibody detects ER only when phosphorylated at Seri 67 with 
no cross-reaction with phosphoiylated isoform ER)3.
Breast cancer sections were used in the work up of this antibody. The product 
datasheet for this antibody suggested heating the sections in lOmM sodium citrate 
buffer for lOminutes. It suggested overnight incubation at 4° at 1:50 dilution (in
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blocking solution). However we decided to follow the protocol already described 
above as used for Seri 18 antibody. This produced some faint staining at the 1:50 
concentration. Antibody concentrations at 1:10, 1:20 were then tried with the 1:10 
concentration demonstrating a good range of staining patterns between sections.
A) Dewax and rehydrate
• Dewax in xylene 2*4 min jI
• Rehydrate in 100% alcohol 2*4 min j
• 90% alcohol 2min |
• 70% alcohol 2min
• rinse in water
B) Antigen retrieval
• 1:10 HER2 Ag retrieval used
• 20min 96°
• 20min cool
• rinse in water
• Incubate sections in 1% H2O2 for 10 mins (13.3ml H2O2 in 400ml d H2O)
C) Staining
• DAKO pen to ring sections
• Incubate in semm free blocking solution for 1 Omin
• Blot serum from sections
• Avidin Biotin Block (Avidin 15min / TBS 5min / Biotin 15 min / TBS 5min)
• Incubate in primary antibody at 4° overnight (1:10 in antibody dilutent)
• Wash TBS 5min
• Incubate in secondaiy antibody (DAKO yellow) for 30 min at room temp
• Wash TBS 5min
98
• Incubate in Streptavidin HRP (DAKO red) for 6Omin at room temp
• Wash TBS 5min
• Incubate in DAB substrate until colour develops (5ml d H2O; add 2 drops 
Buffer, mix, 4 drops DAB stock, mix, 2 drops hydrogen peroxide, mix)
• Wash running water
D) Coimtersiain
• Haemoxylin for 60 sec
• Rinse running water
• Blue with Scotts tap water substitute
• Rinse running water
E) Dehydrate and mount
• 70% alcohol Imin
• 90% alcohol Imin
• 100% alcohol 2*1 min
• xylene 2* Imin
• mount in DPX
99
2.4 Scoring Principles
During the work up of the antibodies, my skills at semi quantitative 
immunohistochemistiy scoring were developed under the guidance of my supervisor 
(JB). Scoring was performed on a light microscope (Laborlux S, Leitz). Prior to any 
final scoring of the TMAs, a series of TMA slides (including the Herceptest and ER 
slides) were double scored, achieving an ICCC (Intra-class correlation coefficient) of
0.94 (n=890) for membrane staining and 0.84 (n=827) for nuclear staining. These 
results indicated excellent correlation between scores. All subsequent cases were 
scored by ST alone. In addition intra-observer correlation was also performed by 
selecting a TMA slide from 6 separate antibody runs (for phospho HER2, phospho 
ER(167), ER, PR, HFRl and H3.105.5) and scored blind by ST on 2 separate 
occasions for each relevant staining modality (membranous, cytoplasmic, nuclear'). 
The Intra-class coefficient correlation (ICCC) score was 0.8282 for membrane scoring 
(n=274), 0.9431 for cytoplasmic scoring (n=345) and 0.9327 (n=422) for nuclear 
staining.
As discussed previously, there have been numerous publications describing the 
discovei-y of protein expression out-with classically expected areas. For this reason, 
for each core scored, we recorded a separate score for any membrane, cytoplasmic or 
nuclear staining seen.
In the absence of any consistent method of scoring most of the antibodies used, we 
elected to use a unifoi'm approach for each staining location.
1. Membrane staining. For any membrane staining demonstrated, I opted to use 
the well described Herceptest system. Cores with over 10% of strong
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membrane staining were assigned 3+; cores with over 10% moderate staining 
were assigned 2+. Cores with over 10% weak staining were assigned 1+.
2. Cytoplasmic staining. For any cytoplasmic staining seen a Histoscore was 
given. This method is well described for cytoplasmic staining and involves 
giving a weighted score for percentages of staining seen. For example, a core 
demonstrating 50% of cells with weak (1+) staining intensity, 20% of cells at 
a moderate (2+) and 20% of cells at a strong (3+) intensity would be given a 
histoscore of 150 (50*1 + 20*2 + 20*3). Thus using this method the maximum 
histoscore that can be achieved is 300.
3. Nuclear staining. Traditionally in the clinical diagnostic setting ER and PR 
scoring has been done using the Allred system (Haiwey et a l, 1999). This 
method involves assigning a proportion score (the estimated proportion of 
positive-staining tumor cells: 0, none; 1, < 1/100; 2, 1/100 to 1/10; 3, 1/10 to 
1/3; 4, 1/3; to 2/3; and 5, > 2/3) and an intensity score (the average intensity of 
positive tumor cells: 0, none; 1, weak, 2, intermediate; and 3, strong). The 
proportion and intensity scores are added to obtain a total score (range from 0 
to 8). An alternative but similar method is the QuickScore (Detre et a l, 1995) 
which is calculated in a similar way but with different cut-offs for the 
proportion score (1=0-4%; 2=5-19%; 3=20-39%; 4=40-59%; 5=6-=79% and 
6=80-100%). Flowever we wished to use a continuous variable method of 
scoring which would also enable ease of correlation with cytoplasmic scoring 
results. We therefore also scored all the nuclear staining using the Histoscore 
method.
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Once individual cores had been individually scored, we then needed to decide on how 
the triplicate cores would be combined to provide one single score for each tumour 
when there was any discrepancy between results. There was little guidance in the 
published literatuie on how this was best achieved. Therefore we developed the 
following approach:
1. Membrane scores. When there was any discrepancy between cores, then the 
percentages stained at each intensity level were combined. For example where 
3 cores were available there would need to be at least 30% combined 
percentage of strong membranous staining for the combined score to be given 
a 3+. If just 2 cores were available the combined percentage would have be at 
least 20% to achieve an intensity level.
2. Cytoplasmic scores. The average histoscore for the available cores was taken.
3. Nuclear scores. The average histoscore for the available cores was taken.
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2.5 Statistical analysis
Suivi val analysis can be performed using a variety of endpoints. Traditionally breast 
cancer related death has been used for analysis of prognostic markers as it is a fixed, 
‘hard’ endpoint. However it can be lead to problems when analysing response to a 
particular therapy as patients relapsing on Tamoxifen would normally be switched to 
alternative endocrine therapies such as aromatase inhibitors, which would confuse any 
data looking at Tamoxifen use only. In addition, for this analysis, we decided to 
terminate follow-up duration after Tamoxifen use was stopped. The advantage of this 
method is that it focuses on patients with disease recurrence whilst on Tamoxifen (i.e. 
'Tamoxifen resistant') and excludes patients who relapse after Tamoxifen use. This 
second set of patients could be theoretically be considered as having potentially 
tamoxifen 'sensitive' tumours, as they were disease free whilst on adjuvant 
Tamoxifen but relapsed when their ti eatment came to an end.
The statistical software package SPSS version 9 was used for all analysis. The Kaplan 
Meier life table statistical analysis was used for analysis of disease free survival 
whilst on Tamoxifen. This was performed over two time periods with respect to HER 
and PR status; throughout the duration of Tamoxifen treatment (to parallel ATAC) or 
after 3 years of Tamoxifen treatment (to parallel the lES trial). Note again that 
patients recurring after termination of adjuvant treatment were classed as censored 
events, as these patients could be classed as relapses because of treatment withdrawal 
rather than because of resistance to Tamoxifen treatment. Cox Regression and Hazard 
Ratio analysis was performed with inclusion of the biological marker alongside 
known prognostic factors size, nodal status and grade. Because of the variety of 
chemotherapy regimes used over the time period of this study, the influence of
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chemotherapy treatment on the relationship between biomarker and tamoxifen 
resistance was not statistically examined. In addition, menopausal status was not 
documented for these patients, however age (above or below 50) was incoiporated as 
a variable in statistical analysis.
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Chapter 3: Results 
3.1 ERa status and patient characteristics of ERa 
positive group
3.1.1 ERa Status
It was particularly important to confirm ERa status in our cohort as in the peiiod over 
which these patients were diagnosed ERa testing moved from ligand binding assays 
to conventional ICH testing. The 15 TMA slides were stained alongside a control 
slides which had been provided by the department of pathology. There was an 
example of a strongly positive, weakly positive and negatively staining breast cancer 
section on the slide and this provided a reference for subsequent scoring. One control 
slide was incubated with an isotype matched antibody and showed no staining.
3.1.2 ERa Staining and scoring
For 34/456 (7.5%) cases there was insufficient material for ERa analysis, either due to 
core loss or insufficient tumour material in cores and these patients were therefore 
excluded from further analysis. Further results and discussion relating to missing/non- 
valid cores will take place later.
Both nuclear and cytoplasmic staining was noted (Appendix Ha). The nuclear staining 
was scored using the Histoscore system as described previously and scores for each 
core were then averaged. ERa slides were double scored for nuclear staining by ST 
and JB and the results averaged. All cases with a nuclear Histoscore 10 or above were 
considered ERa positive (based on current departmental pathology guidelines for 
suitability for endocrine treatment). 20/422 (4.74% of valid cases) were therefore ERa
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negative leaving 402 cases classed as being ERa positive. The 54 ERa negative or 
ERa unknown patients were excluded from any further analysis relating to this study 
with regard to Tamoxifen resistance.
The mean ERa histoscore of the ERa positive (n=402) tumours was 150.46 (S.D. 
57.89) and the median was 153.00 (range 10-300) (Figure 10).
233/402 (57.96%)
100 85/4 0 2 (2 1 .14%) 84/402 (20 .90%
10-100 101-200 201-300
ER nuclear Histoscore Range
Figure 10
ER m id  ear staining: Histoscore intensity andfrequency.
These ERa results were compared to the original results from pathology (performed at 
time of diagnosis, either by IHC or ligand binding) (Table 1). There is a significant 
correlation demonstrated between our TMA results and the pathology results. With 
incorporation of cases labelled weakly positive by pathology into the pathology ER 
positive group, the concordance between TMA and pathology results is 98% (kappa 
.487). Note that 3 cases labelled positive by pathology (all by IHC) were negative 
within the TMA sections. Of those cases labelled weak (all by lElC) by pathology 
4/20 were negative on the TMA sections.
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Table 1
Comparison to pathology ERa status
TMA ERa Total
NEG POS
neg 3 3
PATH ERa status nspos
10
3
61
325
71
328
wk 4 16 20
Total 20 402 422
Comparison o f TMA obtained ERa status with pathology 
department determined ERa status
3.1.3 Patient Characteristics: ER positive only group (n=402)
The original group of ER positive/unknown patients consisted of 686 patients prior to 
exclusions for block unavailability or missing follow-up. The final dataset of our 
TMA classified ER positive patients (n=402) was compared to this original group in 
terms of grade, nodal status, histology, size, Nottingham Prognostic Index (NPI) 
(Galea et al., 1992) and age (Table 2). As can be seen no significant difference can be 
seen between the 2 groups in terms of these clinico-pathological variables (%^ ).
In addition to tamoxifen, 99/399 (24.8%) patients had chemotherapy (3 unknown) and 
110/399 (27.57%) had radiotherapy (3 unknown). The median duration of tamoxifen 
therapy was 5 years (range 0.3-18yrs). The mean follow-up duration is 6.91 years (SD 
3.34 years) and median 6.45 years (range 0.64-18.42 years). There were seventy four 
breast cancer specific deaths. There were one hundred breast cancer relapses, seventy 
eight of which were whilst on Tamoxifen.
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Table 2
Comparison between final data set (n=402) and original pre-excluded group (n=686)
final d a ta  s e t  
num ber/tota l valid  %
P re-exc lu d ed  g ro u p  
nu m ber/total valid%
X2 
p v a lu e
1
G rade ^
m issing
82 /310
154/310
74 /310
92
26 .45
49 .68
23 .8 7
142/569  24 .96  
270 /569  47 .45  
157/569  27 .59  
117
p=0,4868
0
nodal status ^
m issing
193/369
107/369
62 /3 6 9
33
5 2 .3 0
2 9 .0 0
18 .70
340 /612  55 .6  
176/612  28 .8  
96 /612  15.7  
74
p=0.7596
ductal
m issing
322 /397
4 5 /3 9 7
30 /397
5
81.11
11 .33
7.56
522 /659  79 .2  
74/659  11.2  
63 /659  9.6  
27
p=0.5371
T1
T3
m issing
154/380
204 /380
22 /380
22
4 0 .5 3
53 .68
5.79
252 /630  40  
339 /630  53 .8  
39/630  6 .2  
56
p=0.9601
<3.5’S.'
m issing
105/284
135/284
45 /2 8 4
118
36 .97
47 .18
15 .85
145/442  32.8  
213 /442  4 8 .2  
84 /442  19 
244
p=0.3956
a g e  <50  
>50
65
337
16 .17
83 .83
123/686 17.9  
563 /686  82.1
p= 0.6828
The final dataset of our TMA classified ER positive patients (n=402) w as compared to the 
original pre-excluded group in terms o f grade, nodal status, histology, size, Nottingham 
Prognostic Index (NPI) and age. The p value w as calculated from chi-square y2  analysis
The number and timing of recui'rences is shown in Table 3. The average time to 
recurrence on Tamoxifen (n=68) is 2.5 years (SD 1.89 years) with median 2.15 years 
(0.1-8.1 years). The median time on Tamoxifen (for those without recurrence) was 
5yrs.
Table 3
Recurrence Type
R e c u r r e n c e  ty p e F req u en cy P e r c e n ta g e
N one 283 70 .40
On tam oxifen early (years 0-3) 53 13.18
On tam oxifen late (>3years) 25 6.22
After tam oxifen com pletion 34 8.46
S eco n d  Primary 7 1.74
Total 40 2 100 .00
Frequency and percentage o f type and timing o f breast cancer 
recurrence in relation to tamoxifen use.
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3.1.4 ER cytoplasmic staining
The mean cytoplasmic histoscore for the ER positive group was 49.57 (S.D. 36.54) 
and the median 50 (0-150). ER cytoplasmic staining intensity was correlated with ER 
nuclear staining intensity (p<0.001 Kendall’s tau-b).
3.1.5 Disease Free Survival on Tamoxifen: Relationship to intensity of ER 
staining
When the ERa positive cohort was split into groups depending on intensity of ERa 
nuclear staining (i.e. above and below median value) there was no significant 
differences in recurrence on Tamoxifen that could be related to intensity of the 
nuclear staining (p=0.2327). This was also the case when only relapses occurring in 
the first 3yrs where analysed.
Interestingly however, cases without any cytoplasmic staining (n=83) were 
significantly more likely to recur on Tamoxifen (Figure 11, p=0.0127). Note that for 
this, and all following survival curves the time on tamoxifen extends beyond 1 Oyrs as 
several patients in our cohort (especially those on diagnosed earlier) did stay on 
tamoxifen long after the now established 5yr treatment duration.
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1.0
.9
ËRcyto pos(n=319).8
.7
.6
ER cyto neg (n=83)
.5
0 5 10
Time On Tamoxifen
Figure 11
Kaplan-Meier survival cun>es demonstrating cumulative disease free survival 
différences (endpoint o f breast cancer disease relapse whilst on Tamoxifen) between 
patients positive or negative fo r  cytoplasmic ERa staining. Cutoffs fo r  positivity fo r  
variables are defined in the text. P values represent log rank testing o f the difference 
in cumulative disease free survival.
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3.2 Core availability
3.2.1 Missing cores/cores with no tumour
Cores may be invalid because of either core dropout (missing cores) or because the 
core contains no respresentative tumour. An example of the number and percentages 
of cores that are valid/missing can be seen in Table 4 which has been taken from 
results for the ERa antibody. The percentage of cores missing ranged frrom 0-30% 
(average 11,15%) and the percentage with no readily identifable tumour present 
ranged from 16-28.3% (average 22.7%). This meant that the number of valid cores 
ranged from 54-79% (average 66.69%). Cores A to E were constructed 
chronologically and it can be seen that with regards to the core drop out rate this 
improved markedly from over 30% loss for TMA A to less than 3% for TMA E as 
experience of core construction was obtained.
Table 4
Core availability for ERa TMAs
missing no tumour valid
1
A (n=100) 2 
3
30 (30)% 
30(30%) 
43 (43%)
16 (16%) 
23 (23%) 
21 (21%)
54 (54%) 
47 (47%) 
43 (43%)
1
B(n=119) 2 
3
13(10.9%) 
21 (17.6%) 
17(14.3%)
24 (20.2%) 
23 (19.3%) 
21 (17.6%)
82 (68.9%) 
75 (65%) 
81 (68.1%)
1
C (n=100) 2 
3
2(2%) 
2(2%) 
4 (4%)
19(19%) 
19(19%) 
22 (22%)
79 (79%) 
79 (79%) 
74 (74%)
1
D (n=60) 2 
3
3(5%) 
2(3.3%) 
0 (0%)
17 (28.3%)
18(30%)
19(31.7%)
40 (66.7%)
40 (66.7%)
41 (68.3%)
1
E (n=77) 2 
3
2(2.6%)
1(1.3%)
1 (1.3%)
16(20.8%) 
19(24.7%) 
22 (28.6%)
59 (76.6%) 
57 (74%) 
54 (70.1%)
Frequency and percentage o f missing cores, cores with no tumour 
and valid cores for each TMA (A~E). TMAs were constructed in 
triplicate ( 1-3).
I l l
As the TMAS are constructed in triplicate most cases had a least one valid core 
available for analysis. Again using the ERa TMA as an example. Table 5 shows that 
whilst 181/456 (39.7%) had all 3 cores available, only 34/456 had no valid cores. 
Table 6 shows the percentage of cases with one or more valid cores available for 
analysis for each of the antibodies used when analysing results for the ERa positive 
cohort only (n=402). The percentages of cases available for analysis ranges from 
84.83 to 98.88%.
Table 5
Valid cores for ERa TMAS
Valid cores Frequency Percent
0 34 7.50
1 130 28.51
2 111 24.34
3 181 39.69
Total 456 100
Frequency and percentage o f number o f 
valid cores (0-3) for the TMAs stained for 
ERa.
Table 6
Percentage o f cases with valid core(s) for each antibody
Antibody Percentage
PR 96.52
HER1 98.88
HER2 97.5
HER3 H3.105.5 87.81
HER4 H4.77.16 84.83
HER4 HFRl 89.3
pER118 95.52
pER167 90.8
pHER2 93.78
Percentage o f cases with one or more valid cases 
available for analysis for each o f the antibodies when 
analysing the ERa positive cohort only (n=402)
3.2.2 Correlation between core results is marker/antibody dependent
Whilst we have not compared the TMA core results with those from whole sections, 
Table 7 provides some idea of correlations of scores between the cores for each 
antibody. It can be seen that there is a noticeable difference between known, well
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validated antibodies such as ER, PR and HER2 (which demonstrate higher ICCC 
scores) and the phosphorylated antibodies such as pERllS, pER167 and pHER2 
(which show lower ICCC scores). Reasons for this may include the heterogeneity of 
the tissue for these particular receptors in their activated state or may reflect problems 
with pick-up of the phosphorylated state in formalin fixed tissue. Certainly for some 
of these phosphorylated antibodies comparison and correlation with whole tissue 
sections may well be important.
Table 7
Correlation between cores for each antibody 
ICCC between cores for each antibody for those with all 3 valid cores
A n tib o d y n ICCC MEMB ICCC CYTO ICCC IMUC
ER 181 0 .5956 0 .7 1 5 6
PR 228 0 .7 6 4 0
HER2 198 0.7911
HER4 H 4.77 .16 130 0 .2 7 1 4 0 .1746 0.1091
HER4 HFR1 145 0 .3 0 9 0 0 .3274 0 .2 9 2 0
pE R 118 69 0.0961 0 .4766 0 .4 6 6 8
pE R 167 173 0 .2649 0 .5570 0 .2 6 2 6
pHER2 169 0 .2 6 6 7 0 .4376 -0 .0061
Intra-class coefficient correlation (ICCC) scores for each antibody, in each 
cellular location, for those cases with all 3 cores valid.
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3.3 Progesterone (PR)
3.3.1 PR Expression
Both nuclear and cytoplasmic staining was seen (Appendix Hb). All cases with a 
nuclear Histoscore 10 or above were considered PR positive (based on current 
departmental pathology guidelines for reporting PR positivity). There were 241/388 
(62.1%) PR positive patients and 147/388 (37.9%) PR negative cases. The mean PR 
nuclear histoscore is 75.38 (S.D. 87.15) and median 33.75 (range 0-300) (Figure 12). 
There was no significant correlation seen between PR and ER nuclear Histoscore 
values (p=0.309, Kendall’s tau-b).
3.3.2 Sui’vival data
Patients negative for PR were significantly more likely to relapse whilst on 
Tamoxifen (Figure 13, p=0.0017).
147/388  (37.89% )
115 /3 8 8 (2 9 .6 4 % )
7 8 /3 8 8 (1 9 .5 9 % )
50/368  12
0-9 10-100 101-200 201-300
PR nuclear Histoscore Range
Figure 12
PR nuclear staining: Histoscore intensity and frequency.
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I II
PR n eg  (n=147)
.5
100 5
Time On Tamoxifen
Figure 13
Kaplan-Meier sur\nval curves demonstrating cumulative disease free survival 
differences (endpoint o f  breast cancer disease relapse whilst on tamoxifen) between 
patients positive or negative fo r  nuclear PR staining. Cut-offs fo r  positivity fo r  
variables are defined in the text. P values represent log rank testing o f the difference 
in cumulative disease free survival.
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3.4 HER 1-4
3.4.1 HER 1-4 Expression and staining patterns
EGFR/HERl
Only membranous staining was demonstrated for HERl (Appendix lie). The 
frequency and intensity of staining is shown in Figure 14a. Cases with any 
membranous HERl staining were classed as being positive for HERl overexpression 
(6/393, 1.5%).
HER2
Both membranous and cytoplasmic staining was seen (Appendix lid). The slides were 
scored independently by 2 scorers with an ICCC of 0.8863. The mean Herceptest 
score from the 2 scores was taken to the nearest integer. The frequency and intensity 
of HER2 staining are demonstrated in Figure 14b. Patients were considered positive 
for HER2 if they had at least 2+ staining intensity (i.e. at least 10% tumour cells were 
scored as being moderately positive). 51/397 (12.8%) cases were therefore positive 
forHER2.
HER3
Membranous, cytoplasmic and nuclear staining was seen using the H3.105.5 antibody 
(Appendix lie). The membrane score frequency for ERa positive patients is shown in 
Figure 14c. Patients were considered positive for HER3 if they had at least 2+ 
staining intensity at the membrane (i.e. at least 10% tumour cells were scored as being 
moderately positive) resulting in 56/353 (15.9%) cases considered positive. The 
median cytoplasmic histoscore was 83.33 (range 0-265) with mean 93.99 (SD 63.53) 
and the median nuclear score was 58.33 (range 0-250) with mean 61.21 (SD 36.05). 
HER4
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Membranous, cytoplasmic and nuclear staining was seen using the H4.77.16 antibody 
(Appendix Ilf). Membrane score frequency for ERa positive patients is shown in 
Figure 14d. Patients were considered positive for HER4 if they had at least 2+ 
staining intensity (i.e. at least 10% tumour cells were scored as being moderately 
positive). 46/341 (13.5%) cases were positive for HER4. The median cytoplasmic 
score was 38.33 (range 0-250) with mean 48.57 (SD 50.83). The median nuclear score 
was 0 (range 0-200) with mean 15.01 (SD 26.42).
These findings correlate with our previously published results in ER positive cancer 
where we demonstrated 3.0% patients were EGFR positive, 11.2% HER2 positive, 
11.0% HER3 positive and 16.5% HER4 positive (Witton et al., 2003). A recent large 
study showed generally higher rates of positivity throughout with 14.0% positive for 
EGFR, 29.3% for HER2, 45% for HER3 and 44.9% for HER4 (Abd El-Rehim et al., 
2004). This study used different antibodies and a different method of identifying 
cutoff levels than our study.
3.4.2 Sui’vival and disease free analysis
Despite a marked separation of the relapse free survival cuiwes for HERl positive 
patients relapsing on Tamoxifen, statistical significance in this small group was not 
reached (Figure 15a p-0.4739). HER2 and HER3 positive patients were significantly 
more likely to relapse on Tamoxifen (Figure 15b & 15c, p=0.0280, p=0.0278 
respectively). However HER4 positive patients showed no significant difference in 
survival on Tamoxifen (Figure 15d, p=0.2159).
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Figure 14a Figure 14b
400-, 387/393 (98.47%)
1/393 (0.25%) 2/393m (0.051%) 3/393(0.75% )
N egative  1+ 2 + 3+
E G FR  m e n b ra n e  In tensity
290/397 (73.05%)
56/397 (14.11%)
26/397 (6.55%) 25/397 (6.30%)
N egative 1+ 2+
H ER 2 m e m b ra n e  Intensity
Figure 14c
208/353 (59.92%)
89/353(25.21%)
56/393(15.86%)
N egative 1+ 2+ 3+
H ER3 m em b ran e  n ten sity
Figure 14d
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Figure 14
Frequency histograms fo r  membrane staining intensity fo r  a) HERl, b) HER2, c) 
HER2 and d) HER4.
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Figure 15
Kaplan-Meier sun>ival cun>es demonstrating cumulative disease free suiMval 
differences (endpoint o f breast cancer disease relapse whilst on tamoxifen) between 
patients positive or negative fo r  a) HERl, b) HER2, c) HER3 and d) HER4. Cut-offs 
fo r  positivity fo r  variables are defined in the text. P values represent log rank testing 
o f the difference in cumulative disease free sunnval.
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3.4.3 Coexpression of HERl-4 antibodies.
The following illustrates the co-expression patterns of the H ERl-4 family.
1.HERl: 6/ 393(1.5%) positive
• 1/6 also positive for HER4
• 1/6 also positive for HER3 and HER4
• 1/6 also positive for HER2, HER3 and HER4
• 3/6 positive for HERl alone
2.HER2: 51/397 (12.85%) positive
• 7/51 also positive for HER3
• 3/51 also positive for HER4
• 5/51 also positive for HER3 and HER4
• 1/51 also positive for H ER l, HER3 and HER4
• 35/51 positive for HER2 alone
3.HER3 56/353 (15.86%) positive
• 7/56 positive for HER2
• 17/56 also positive for HER4
• 1/56 also positive for HERl and HER4
• 5/56 also positive for HER2 and HER4
• 1/56 also positive for H ER l, HER2 and HER4
• 25/56 positive for HER3 alone
4. HER4 46/341 (13.5%)
• 1/46 also positive for HERl
• 3/46 also positive for HER2
• 17/46 also positive for HER3
• 1/46 also positive for HERl and HER3
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• 5/46 also positive for HER2 and HER3
• 1/46 also positive for HERl, HER2 and HER3
• 18/46 positive for HER4 alone
There were significant correlations between expression of EGFR and HER4 (p=0.019, 
Fishers exact test), between HER2 and HER3 (p=0.030, and between HER3 and 
HER4 (p<0.001, f ) .
98/350 (28%) patients were positive for either one of HERl, HER2 or HER3 (HERl- 
3), and H ER l-3 positivity predicted for early relapse on Tamoxifen (p=0.0060, Fig 
16a). Interestingly the trend for relapse on Tamoxifen appears to increase if  patients 
are positive for more than one HER family member (p=0.0093, Figure 16b).
Figure 16a Figure 16b
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Figure 16
Kaplan-Meier survival curves demonstrating cumulative disease free survival 
differences between a) patients positive or negative fo r  HERl-3 (positive fo r  either 
one o f HERl, HER2 or HER3). b) patients positive fo r  more than one H E R l-3 family 
member, patients positive fo r  only one type o f  HER receptor and patients negative fo r  
all HER family members. Cutoffs fo r  positivity fo r  variables are defined in the text. P 
values represent log rank testing o f the difference in cumulative disease free siuMval
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3.4.4 Correlation with PR status and relationship with smwival
Table 8 shows the relationsliip between PR and each HERl-3 member. HER3 shows a 
significant inverse relationship with PR (p=0,001, There is no significant 
relationship between PR and either HERl or HER2, although when the group is 
combined as H ERl-3 the significant inverse relationship persists (p=0.001, y^).
Table 8
Relationship between PR and HER status.
HER1 
neg pos
HER2 
neg pos
HER3 
neg pos
HERl-3 
neg pos
PR pos
141 2 
236  4
120 22  
213  28
94 31 
197 25
74 48  
174 49
Total
Patients positive
377  6
for HER1, HER2,
333  50
HER3 or HER1-3 c
291 56
',ombined (c a s e s  p<
2 4 8  97
ositive for one or
more o f HER1 HER2 or HER3) with respect to PR status. Cut-offs for positivity are defined 
in the text.
Figure 17 shows the significantly increased rate of relapse on Tamoxifen (p<0.0001) 
when H ERl-3 positive and/or PR negative patients are combined as a poor prognostic 
group. This ‘high risk’ H ER l-3 positive/PR negative group also predicted for 
increased relapse in Cox’s multivariate analysis (p=0.0069) when analysed alongside 
known prognostic variables size, grade and nodal status.
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Figure 17
Kaplan-Meier survival cur\’es demonstrating cumulative disease free survival 
differences between patients either HERl-3 positive and/or PR negative and patients 
HERl-3 negative and PR positive. Cutoffs fo r  positivity fo r  variables are defined in 
the text. P values represent log rank testing o f the difference in cumulative disease 
free sun’ival.
3.4.5 Analysis of molecular markers as time dependent variables
Kaplan-Meier suivival analysis was subsequently peiformed following exclusion of 
those patients who relapsed during the first 3 years of treatment, with the aim of 
focussing on those patients who had later relapses. Using this method of analysis the 
PR negative/HERl -3 positive group no longer demonstrated any significant 
difference in recuirence rates on Tamoxifen (p=0.0858).
Table 9 shows the number (and percentages) of recurrences on Tamoxifen in years 1- 
3 compared to years 4-5 in the high/low risk groups as identified by the relevant 
molecular markers. (Note that only patients remaining disease free  at 3 years are 
included in the year 4-5 group). It also shows the Hazard ratios (95% Cl) from Cox’s 
multiple regression with the relevant factors analysed alongside size, nodal status and 
grade. The p-values from this analysis demonstrate a significant difference between
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recurrences in the high versus low risk groups when analysed for the years 1-3, whilst 
PR and H ER l-4 status has no significant impact on recunences in years 4-5.
Table 9
Time dependent analysis o f  variables.
HERl-3 PkR HERl-3 i)os/PR neg
Years Positive Negative Hazard
Ratio
Positive Negative Hazard
Ratio
High risk Low Risk Hazard
Ratio
1-3 21/98
21.4%
25/251
10.0%
2.18
(1.13-
4.21)
p=0.01
89
22/240
9.2%
31/147
21.1%
0.48
(0.26-
0.92)
p=0.025
4
39/197
19.8%
11/173
6.4%
3.08
(1.40-
6.8)
p=0.005
2
4-5 3/70
4.3%
7/204
3.4%
0.96
(0.18-
5.05)
p=0.96
11
8/204
3.9%
5/108
4.6%
1.62
(0.39-
6.68)
p=0.501
6
8/147
5.4%
5/152
3.3%
0.91
(0.23-
3.64)
p=0.899
0
HER1-3 positive  =  cases expressing one o r more o f HER, HER2, HER3 above the cut offs defined in the 
text. HER1-3 negative  =  cases negative for a ll three receptors. PR positive  =  cases expressing  
progesterone receptors. PR negative  =  cases lacking progesterone receptor expression. C om bined High 
R isk = cases e ither HER1-3 pos and/or PgR negative, Low  risk = cases both HER1-3 negative and PgR  
positive. Hazard Ratio  =  relative increased haza rd  (with 95% confidence intervals in brackets) from  
Cox's regression analysis fo rH E R 1-3  positive versus HER1-3 negative cases, PgR positive versus PR  
negative and  H igh versus Low  risk cases respectively. Years 1-3 (4-5) =  patients at r isk (denom inator) 
and num bers o f  re lapses (numerator) within different subgroups during years 1-3 (4-5  =  in years 4 and  
5) o f tamoxifen treatm ent only. Percentages  =  percentage relapse rates in a t risk population during time 
period  in question. P values derived from C ox’s  m ultiple regression analysis
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3.5 Phosphorylated ER
3,5,1 pERaSeiTlS and pERaSeiT67 expression
Nuclear, cytoplasmic and membranous staining was observed for both pERaSerllS 
and pERaSerl67 (Appendix Eg and Ilh and Figures 18 a-f). For pERaSerl 18, 12.5% 
(48/384) showed membranous staining, 94.3% (362/384) exhibited cytoplasmic 
staining (median histoscore 175 (range 0-300), mean 163.69 (SD 81.60)) and 98.4% 
(378/384) exhibited nuclear staining (median score of 145 (range 0-270), mean 
141.77 (SD 47.12)). For pERaSerl67, 20.8% (76/365) showed membranous staining, 
70.68% (258/365) exhibited cytoplasmic staining (median histoscore 50 (range 0- 
250), mean 60.42 (SD 55.71)) and 95.6% (349/365) demonstrated nuclear staining 
(median histoscore 96.70 (range 0-250), mean 102.16 (SD 55.45)).
There were significant conelations between the intensity of nuclear pERaSeiTlB and 
nucleai- pERaSerl67 staining (p<0.001, Kendall’s tau-b) and between cytoplasmic 
pERaSerllS and cytoplasmic pERaSerl67 staining intensity (p<0.001, Kendall’s tau- 
b). There was also overlap between membranous staining with 25/357 cases 
exhibiting staining for both pERaSerl 18 and pERaSerl 67 at the membrane.
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Figure 18
Frequency histograms fo r  membranous a) pERaSerllS and b) pERaSerl67 staining; 
cytoplasmic c) pE R aSerllS  and d) pERaSerl67staining; and nuclear e) pERaSerllS  
andf) pERaSerl 67 staining
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3.5.2 Relationship between phosphoiylated ERa and ERa status
Nucleai' and cytoplasmic pERaSerllS staining correlated significantly with the 
intensity of ERa nuclear staining (p<0.001 and p=0.006 respectively, Kendall’s tau-b, 
Table 10) as did nuclear and cytoplasmic pERaSerl67 staining (both p<0.001; 
Kendall’s tau-b).
In addition nuclear and cytoplasmic pERaSerl 18 staining correlated significantly 
with the intensity of ERa cytoplasmic staining (p=0.004 and p<0.001 respectively, 
Kendall’s tau-b) as did nuclear and cytoplasmic pERaSerl67 staining (p=0.003 and 
p<0.001; Kendall’s tau-b).
However there was no correlation between the intensity of nuclear ERa staining and 
the presence of either membranous pERaSerl 18 or pERaSerl 67 expression (Mann- 
Whitney, Table 10). There was also no correlation between cytoplasmic ERa staining 
and the presence of membranous pERaSerl 18 although there was a significant 
correlation with the presence of membranous pERal 67 (Mann Whitney, p<0.001)
3.5.3 Relationship between phosphoi^lated ERa and PR status
There was no correlation between PR positivity and either nuclear or cytoplasmic 
pERaSerl 18 or pERaSerl 67 histoscores (Mann Whitney) or presence of membranous 
pERaSerl 18 (p=0.082, or pERaSerl67 (p=0.139, %^).
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Table 10
Relationship between pER SerllS , pERSer167 and nuclear ER and H ER l-3  
expression
ERa HERl-3
nuclear ER cytoplasm ic ER
nuclear p<o.oor p=0.004* p=0.006**
pERaSerl 18 cytoplasm ic p=0.006* p<o.oor p=0.294**
m em brane p=0.407** p=0.496** p<0.001***
nuclear p<0.001* p=0.003* p=0.522**
pERaSer167 cytoplasm ic p<0.001* p<0.001* p=0.229**
m em brane p=0.133** p<0.001** p=0,002***
*KendaH's tau-b, **Mann-\A/hitney, ***x2 
b o ld = p o s it iv e  co rre la tio n , italic-negative correlation
pE R aS erl 18 represents phosphorylated ERa at Ser118 at nucleus,cytoplasm and 
membrane. p E R a S e rl67 represents phosphorylated ERa at S e ri67 at nucleus, 
cytoplasm and membrane. ERa represents nuclear or cytoplasmic staining ERa  
staining. H ER l-3  represents patients positive for one o f HERl, HER2 and/or HER3 
at the membrane.
3.5.4 Relationship between phosphoi'ylated ERa and HERl-3 status
Nuclear pERaSerllS staining was negatively correlated with HER 1-3 overexpression 
(p=0.006, Mann-Whitney) but there was no association between nuclear pERaSerl 67 
and HERl-3 expression (p=0.522). In addition there was no correlation between 
cytoplasmic pERaSerl 1S or pERaSerl67 and HERl-3 expression (Mann Whitney). 
However, the presence of both membranous pERaSerllS and membranous 
pERaSerl67 was significantly correlated with HERl-3 positivity (p<0.001 and 
p=0.002 respectively; Pearsons yl. Table 10).
3.5.5 Correlation with relapse on tamoxifen and known clinical prognostic 
markers
Increased nuclear pERaSerl 67 correlated with smaller size and lower grade of tumour 
(p<0.001 and p=0.001 respectively, Kendall’s tau-b) and cytoplasmic pERaSerl67 
intensity correlated with small tumour size (p<0.001). However the presence of 
membranous pERaSerl 18 was associated with larger tumours (p=0.009, Pearsons %2).
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Nuclear and cytoplasmic pERaSerllS and membranous pERaSerl67 did not 
correlate with nodal status, grade or size of tumour.
Whilst there was no significant association between phosphoiylated ERa at the 
nucleus or cytoplasm and relapse on tamoxifen, patients positive for membranous 
pERaSerllS were significantly more likely to have disease relapse (p==0.0412, Figure 
19). No such association was observed with membranous pERaSerl 67 (p=0.8472).
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Figure 19
Kaplan-Meier siuMval ounces demonstrating cumulative disease free survival 
differences (endpoint o f  breast cancer disease relapse whilst on tamoxifen) between 
patients positive or negative fo r  membranous pERaSerllS. Cut-offs fo r  positivity fo r  
variables are defined in the text. P values represent log rank testing o f the difference 
in cumulative disease free siu^ival.
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3.6 Comparison of HER4 antibodies.
3.6.1 Cut-offs determining membranous, cytoplasmic and nuclear staining status
Membranous, cytoplasmic and nuclear staining was seen using both H4.77.16 
(Appendix Ilg) and HFRl (Appendix Hi) antibodies. To compare the respective 
staining of the two antibodies, cutoffs were chosen to determine positive or negative 
staining for the respective modalities. For membranous HER4 any staining at the 2+ 
or higher level was chosen as described previously. Cases were considered positive 
for cytoplasmic or nuclear staining if the average histoscore for the respective 
modality was over 10. Concordance between two antibodies, with regard to staining at 
the membrane, cytoplasm and nucleus, was evaluated using chi-square kappa value 
where a value of 1 indicates perfect agreement and a value of 0 indicates that 
agreement is no better than chance.
3.6.2 Membrane staining
Membrane staining intensities for each antibody are shown (Figure 20a & b). 46/341 
(11.4%) patients were classed as positive using the H4.77.16 antibody and 28/359 
(7.0%) using the FlFRl antibody. The concordance between the 2 antibody results is 
88.44% (n=329, Table 11) with a kappa value of 0.426 (where a value of 1 indicates 
perfect agreement and a value of 0 indicates that agreement no better than chance). It 
can be seen that the percentage of tumours that are negative is similar between the 2 
antibodies but that the H4.77.16 antibody appears to detect a stronger intensity of 
staining at the membrane. This may reflect a difference in sensitivity between the 
antibodies or alternatively reflect a difference between TACE cleaved but y-secretase 
intact HER4.
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3.6.3 Cytoplasmic staining
The median cytoplasmic histoscore for H4.77.16 antibody was 36.67 (range 0-250) 
and mean 48.21 (SD 50.32). The median cytoplasmic histoscore for HFRl was 75 
(range 0-253) and mean 78.75 (SD 61.10). The HFRl antibody therefore has 
generally has higher levels of cytoplasmic staining (Figmes 120c & d). 225/341 
(66.0%) patients were classed as positive using the H4.77.16 antibody and 293/359 
(81.6%) using the HFRl antibody. The concordance between the 2 antibody results is 
74.77% (n=329, Table 11) with a kappa value of 0.351. This difference may reflect 
the fact that HFRl can recognise both cleaved 4ICD and the intact (recycling) HER4 
whilst H4.77.16 will recognise the intact form only.
3.6.4 Nuclear staining
The median nuclear score for H4.77.16 antibody was 0 (range 0-200) and mean 15.01 
(SD 26.42). The median nuclear score for HFRl was 63.33 (range 0-200) and mean 
64.83 (SD 38.65). The antibodies showed veiy different staining patterns in the 
nucleus (Figures 20e & f). 116/341 (34.0%) patients were classed as positive using 
the H4.77.16 antibody and 332/359 (89.3%) using the HFRl antibody. Whilst over 
60% of patients stained with the H4.77.16 had no nuclear staining, the vast majority 
showed some staining with the HFRl antibody. Once split into positive and negative 
groups the concordance between the 2 antibody results is 40.12% (n=329, Table 11) 
with a kappa value of 0.051. This lack of agreement may well reflect the fact that the 
cleaved 4ICD (recognised by HFRl) is much more likely to be found in the nucleus 
than the intact form.
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Figure 20
Frequency histograms fo r  membranous (a & b), cytoplasmic (c & d) and nuclear (e & 
f)  staining intensity using the H 4.77.16 and HFRl antibodies.
132
Table 11
Comparison o f H4.77.16 and H FR l staining patterns in the membrane,
cytoplasm and nucleus
M em b ran e H 4 .77 .16
n eg pos total kappa value
neg 273 28 301
HFR l p os 10 18 28 0 .426  (p<0.001)
total 283 46 329
C y to p la sm ic H 4.77 .16
neg p os total kappa value
n eg 41 15 56
HFR1 pos 68 205 273 0.351 p<0.0001
total 109 220 329
N u c lea r H 4.77.16
n eg p os total kappa value
n eg 21 3 24
HFR1 p os 194 111 305 0.051 (p=0.018)
total 215 114 329
Chi- square where numbers o f cases negative orpostitive for each 
antibody in at either the membrane, cytoplasm or nucleus are shown using 
cutoffs defined in the text Cohen's Kappa value measures the agreement 
between the 2 antibodies where a value o f 1 indicates perfect agreement 
and a value o f 0 indicates that agreement is no better than chance
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3.6.5 Relationship with clinicopathological variables and the other HER family 
members.
Both antibodies demonstrated a significant relationship between membranous HER4 
and increasing size and HER3 positivity (Table 12). For the patients positive for 
F1ER4 using the HFRl antibody; 22/28 (78.57%) were also positive for another 
member of the HER family. For the H4.77.16 this figure was 28/46 (60.87%).
Table 12
JR H4.77.16 membrane 
p value correlation x'
HFR1 membrane
p value correlation
NPI 4 .7 9 9 0.091 6 .0 9 5 0 .047 p os
size 8 .652 0 .013 pos 8 .608 0 .008 p os
grade 2 .4 5 3 0 .293 0.75 0 .687
nodal 1 .769 0 .413 3 .202 0 .202
egfr Fishers 0 .019 pos Fishers 0 .074
her2 1 .657 0 .243 Fishers 0 .314
her3 53 .6 7 <0.001 pos Fishers <0.001 p os
Grade = Bloom and Richardson grade. Nodal status = number o f positive nodes. NPI 
= Nottingham Prognostic Index (grade+nodal status+ 0.02*size in mm).
Both antibodies showed a correlation between HER4 cytoplasmic staining and 
increasing NFI, nodal status, size and HER3 positivity (Table 13). Neither antibody 
showed any significant correlations between nuclear HER4 staining and pathological 
variables or HERl-3 status.
Table 13
test
H4.77.16 histoscore 
p value correlation
HFR1 histoscore 
p value correlation
NPI Kendall's tau-b 0 .004 pos <0.001 pos
size Kendall's tau-b <0.001 p os 0.021 pos
grade Kendall's tau-b 0 .0 7 6 <0.001 p os
nodal Kendall's tau-b 0 .0 0 4 p os <0.001 p os
egfr Mann-W hitney 0 .035 0 .436
her2 Mann-W hitney 0.381 0.771
her3 Mann-W hitney <0.001 p os 0.001 p os
Grade = Bloom and Richardson grade. Nodal status = number o f positive nodes. NPI 
Nottingham Prognostic Index (grade+nodal status+ 0.02*size in mm).
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3.6.6 Suï’vival and disease free analysis.
For both antibodies there was no relationship between disease free or overall survival 
and membranous HER4 staining. Cases who were positive for HER4 only (and not for 
any other members of the HER family) where identified (n=6 for HFRl and n=18 for 
H4.77.16) but these patients again did not have significantly different rates of 
suiwival. Cytoplasmic staining was not correlated with disease free or overall survival 
using either antibody. However cases demonstrating nuclear HER4 staining using the 
H4.77.16 antibody were significantly more likely to have poorer overall survival 
(p=0.0124, Figure 21). There was no such correlation with survival with the HFRl 
antibody.
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Figure 21
Kaplan-Meier survival curves demonstrating cumulative disease free smMval 
differences (endpoint o f breast cancer disease relapse whilst on tamoxifen) between 
patients positive or negative fo r  nuclear HER4 using the H4.77.16 antibody. Cutoffs 
fo r  positivity fo r  variables are defined in the text. P values represent log rank testing 
o f the difference in cumulative disease free survival.
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3.7 pHER2 antibody
3.7.1 pHER2 staining
Membranous, cytoplasmic and nuclear staining was seen (Appendix Ij). Intensity of 
membranous staining can be seen in Figure 22. Using 2+ scoring intensity as a cutoff 
there are 24/366 (6.37%) positive for phosphoiylated HER2.
217/377 (07.6%)
136/377 (36.1%)
24/377 (6,4%)
N egative 1+ 2+
Phosphory lated  H ER2 m em brane ntensily
Figure 22
Frequency histogram showing intensity o f  membranous phosphorylated HER2 
staining
3.7.2 Sui’vival and disease free analysis
Neither membranous, cytoplasmic nor nuclear staining positivity was correlated with 
disease free suiwival on tamoxifen. In addition there was no correlation with known 
prognostic variables, size, grade and nodal status.
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3.7.3 Relationship between pHER2 and HercepTest scores.
There is no significant relationship (%2 p=0.938, Table 14) between the intensity of 
membrane staining for HER2 and phosphorylated HER2 staining. Indeed many cells 
negative for Herceptest showed staining for phosphorylated HER2.
Table 14
Relationship between HER2 and Phospho-HER2 scoring
P h o sp h o -H E R 2  
0 1+ 2+
Total
H e r e c e p e s t 0 157 100 16 273
1 + 31 19 3 53
2+ 15 8 2 25
3+ 14 8 3 25
Total 217 135 24 376
Relationship between membranous HER2 and membranous 
Phospho-HER2 scoring, intensity scored as 1+(weak), 
2+(moderate) or 3+ (strong) staining.
Our results did not support the previously published reports suggesting that that 
pHER2 status provided improved prognostic information compared to HER2 status 
alone (Thor et a l, 2000). Therefore no further analysis was performed using these 
results.
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Chapter 4 Discussion
4.1 TMA validity and Limitations of the study
We have demonstrated that TMA technology can be used successfully to quickly 
process large numbers of cases though imniunohistochemistiy protocols in a limited 
amount of time. In addition we were able to peiform direct comparison of staining 
intensities between specimens so improving the subjective inteipretation of results. 
However as other studies have shown, we also had significant rates of core loss.
The overall percentage of cores missing was 11.15% and the percentage with no 
readily identifable tumour present was 22.7%. This meant that the number of valid 
cores ranged from 54-79% (average 66.69%). This is in keeping with published 
results (Bubendorf et a l, 1999; Hoos and Cordon-Cardo, 2001; Schraml et al., 1999; 
Torhorst et a l, 2001). Of note, the core drop out rate improved markedly as 
experience of TMA constmction was obtained suggesting that core loss is dependent 
on operator experience. As predicted, constructing the TMAS in triplicate minimised 
the impact seen because of core loss. Depending on the antibody, the percentages of 
cases with at least one valid core ranged from 84.83 to 98.88 %. These figures 
suggest that using 4 cores per case may have improved the availability of valid cores 
for analysis.
Concerns have also been raised with regard to the impact of tissue heterogeneity on 
TMA results although it must be remembered that a tumour block itself often 
represents a small fraction of the actual tumour. Evidence comparing core and whole 
section results has suggested that this problem is minimised by having more than one 
core available for analysis (Hoos and Cordon-Cardo, 2001; Camp et a l, 2000). We 
have not compared TMA results to those of whole sections; however we did
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determine the correlation between core results in those cases that had all 3 cores 
available. This demonstrated a noticeable difference between known, well validated 
antibodies such as ER, PR and HER2 which demonstrate higher ICCC scores, and the 
phosphorylated antibodies such as pERllS , pER167 and pHER2 which show lower 
ICCC scores. The discrepancy in these results may result from the heterogeneity of 
the tissue for these particular receptors in their activated state or may reflect problems 
with pick-up of the phosphoiylated state in formalin fixed tissue. In addition some of 
the less well validated antibodies had more evidence of background staining 
compared to Herceptest staining for example. Certainly for some of these 
phosphoiylated antibodies, correlation with whole tissue sections may well be 
important.
One concern with regard to analysis of multiple testing of variables is the possibility 
that “significant” associations are being demonstrated due to ‘chance’ rather than 
being due to a true correlation. For an acceptable significance of p=0.05 this would 
occur in 1 in 20 tests. Whilst the majority of this study is based on suiwival analysis, 
multiple correlations have been peiformed particularly in comparison of HER4 
antibody staining. One method of adjusting for this would be to perform the 
Bonferroni test, based on Student’s t statistic, which adjusts the observed significance 
level for the fact that multiple comparisons are made (Bland and Altman, 1995). 
However it must also be noted that all analysis performed in this study were on a pre­
planned basis and in addition the majority of correlations analysed have been 
statistically significant.
The findings in this thesis highlight the problems of comparative analysis within the 
literature with regard to identification of prognostic/predictive markers. The use of 
different antibodies, scoring systems, conditions and comparison of TMAs with whole
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sections all make comparative analysis difficult. A recent meeting on Cancer 
Diagnostics (NCI-EORTC) has led to the development of REMARK guidelines 
(McShane et al., 2005) which provide suggestions on how both the trial design and 
reporting of results of marker based studies can be standardised to improve the ability 
to compare results across studies.
One recent advance in immunohistochemical based marker studies has been the use of 
automated image analysis (Camp et al., 2002). There are various systems on the 
market including ACIS (ChromoVision) and AQUA (HistoRx). Whilst automated 
image analysis is becoming more commonplace in pathology laboratories it has its 
drawbacks. Whereas an experienced pathologist can score only tumour cell 
immimoreactivity, this may not be true of a machine, and overestimates of postivity 
might ensue. This is paiticularly important when considering location of staining, 
where detection of staining at the nucleus, cytoplasm or membrane may have veiy 
different prognostic implications. However use of image analysis technology is 
particularly attractive in terms of image capture for storage of the image for future 
analysis and for ease of inter-scorer comparision.
Whilst IHC based marker studies continue to be used to identify new prognostic 
markers, other emerging approaches such as reverse transcription polymerase chain 
reaction and DNA microarrays are increasingly used as prognostic or predictive tests. 
For example Oncotype DX (Genomic Health Ltd) represents an important conceptual 
advance in the diagnosis of ER positive cancers. This RT-PCR based assay measures 
ER mRNA expression as well as the expression of several downstream ER-regulated 
genes (PR, BCL-2, SCUBE-2) that may represent a functional ER (Paik et al., 2004). 
The use of high throughput gene-expression profiling techniques has lead to the 
identification of subsets of breast cancers with different molecular signatures. One
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such comprehensive study using hierarchical clustering has suggested that gene- 
expression patterns of breast cancer can be split into 4 major classes; luminal-like 
(usually ER positive), basal-like (mostly ER negative), normal-like and HER2- 
positive (Pérou et a l, 2000). This technique has also been used to identify a 70-gene 
prognostic predictor for increased chance of relapse (van de Vijver et a l, 2002; 't 
Veer et a l, 2002). However with all new technologies, reproducibility of results and 
standardisation of methodology must be determined. Promising markers identified 
using these methods must investigated in laboratory to gain insight into their function 
before being considered as new diagnostic markers (Pusztai et a l, 2006).
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4.3 HERl-3 positive and/or PR negative patients are 
associated with early relapse on tamoxifen.
We have demonstrated results which confirm the significant role played by the type I 
receptor tyrosine kinases HERl, HER2 & HER3 in promoting tamoxifen resistance in 
homione responsive breast cancers. The results also emphasise the different role of 
HER4 in this context. In addition, these data demonstrate that PR negative tumours 
have a reduced responsiveness to tamoxifen which is only weakly related to 
expression of HERl-3. Therefore a phenotype of either HERl-3 positivity or PR 
negativity in ER positive breast cancers appears to be linked to tamoxifen resistance - 
as defined by elevated risk of disease relapse despite endocrine therapy. Strikingly, 
however, it appears that this elevated risk applies in the first 3 years of tamoxifen 
therapy only. Most interestingly, these data appear to explain recently reported 
discrepancies relating to PR status and aromatase inhibitors in clinical trials 
(Coombes et al., 2004a; Dowsett, 2003).
Previously we have demonstrated that expression of HERl-3 is linked to high 
proliferation indices in breast cancer, whilst HER4 is associated with a low 
proliferation index (Tovey et al., 2004). Furthermore, preliminary data suggested that 
patients with ER positive disease were at greater risk of early relapse due to HERl-3 
expression than ER negative cases (Witton et al., 2003). Now we have analysed the 
expression of the type I receptor tyrosine kinases (HERl-4) in a large retrospective 
group of tamoxifen treated, ER positive cases. Patients whose tumours were positive 
for HERl-3 were shown to be at a significantly greater risk of relapse whilst on 
adjuvant tamoxifen, supporting a role for the HERl-3 receptors in tamoxifen
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resistance (figmes 15 & 16). Conversely, we show no relationship between the 
expression of HER4 and early relapse on tamoxifen supporting growing evidence that 
this receptor type plays a distinct role to other members of the type I RTK family. 
Further discussion with regard to HER4 and its role in breast cancer will occur later. 
Our results also suggest that the overexpression of more than one HER family 
member significantly increases the likelihood of relapse on tamoxifen (figure 16). 
Similar evidence from a recent report (Abd El-Rehim et al., 2004) and our earlier data 
(Witton et a l, 2003) supports an additional negative effect on outcome when multiple 
receptors are co-expressed. The ability of HER2 and HER3 to potentiate signalling 
through other receptors has been demonstrated in vitro (Yarden, 2001b) suggesting 
this is a possible mechanism by which heterodimers may produce a more marked 
effect than homodimers. We know that HER2 enhances and stabilises dimerization 
but apparently has no ligand (Klapper et a l, 1999) whereas HER3 has no inherent 
kinase activity so must be dimerised with another HER family member to exert an 
influence on downstream signalling (Guy et a l, 1994). Evidence has suggested that 
this HER2-HER3 heterodimer is the most potent combination of all (Yarden, 2001a). 
Whilst some of the most convincing published clinical evidence for the role of HERl 
and 2 in tamoxifen resistance has come from neo-adjuvant trials (Ellis et a l, 2001) the 
major adjuvant trials comparing tamoxifen to aromatase inhibitors have largely failed 
to build this in to planned prospective analysis. However there has been some data 
from the AT AC (Dowsett, 2003) suggesting that differences do exist in the molecular 
profile of patients who respond to early aromatase inhibitors in preference to 
tamoxifen when analysed in regard to the PR status of the patients. Our results 
confirm suggestions that ER positive/PR negative tumours are significantly less likely 
to respond to tamoxifen treatment than ER positive/PR positive tumours (Coombes et
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al, 2004a; Dowsett, 2003).This is of particular current interest given the ATAC and 
lES evidence with regard to PR. The ATAC trial was designed to compare the 
efficacy of tamoxifen versus the aromatase inhibitor Arimidex (either alone or in 
combination) in ER positive post menopausal women. Early results from this trial 
demonstrate a superiority of Arimidex over tamoxifen in terms of disease free 
suiwival However, retrospective sub analysis from this trial also suggested that this 
increased clinical benefit derived from Arimidex was particularly evident in the PR 
negative tumour patients (Dowsett, 2003).
The inverse relationship demonstrated here between PR and HER 1-3 expression 
(Table 8) might support supposition that PR negativity may be acting as a suixogate 
marker for HERl-3 overexpression in the ATAC trial This would link the ATAC 
data with data from the neoadjuvant trials (Ellis et al, 2001; Ellis et a l, 2003) 
demonstrating that aromatase inhibitors circumvent HERl/2 mediated tamoxifen 
resistance in vivo. However, closer examination of the evidence presented here 
confirms that ER positive/PR negative tumours and HERl-3 positive tumours 
represent distinct patient sub-groups with relatively little overlap. Only 12% (42) of 
tumours were both PR negative and HERl-3 positive with 19.1% PR negative/HERl- 
3 negative and 15.3% PRpositive/HERl-3 positive. This suggests that the association 
between HERl-3 expression and loss of PR expression, whilst real, is weak and that 
alternative, as yet unexplained, mechanisms must underpin tamoxifen resistance in PR 
negative tumours. PR expression has long been thought to reflect a functional, ER 
transcription pathway. It is possible that the ER in these PR negative patients is not 
functioning as a nuclear receptor, but instead is active through non genomic 
mechanisms either in the cytoplasm or at the membrane where it may interact with the 
HER family or other active signal transduction pathways. However, evidence relating
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to the expression of different PR isoforms, and potentially ERp, as predictors of 
tamoxifen response may also be of importance (Bardou et al., 2003; Isaksson et al., 
2003; Iwase et al., 2003). Further work is required to investigate these potential 
explanations. However, our data suggests that in both HERl-3 positive and PR 
negative breast cancers there is evidence of resistance to tamoxifen (this group 
represents almost 50% of all ER positive cancers in this study). In these patients, 
based on published evidence from the ATAC trial and from Ellis’ group, we 
hypothesise that enhanced response rates could be obtained by use of aromatase 
inhibitors in place of tamoxifen at an early stage. Conversely, we hypothesise, many 
other patients, particularly those with HERl-3 negative and PR negative tumours, 
may continue to derive significant benefit from tamoxifen without the need to switch 
to aromatase inhibitors.
However, this conclusion would initially appear to be contradicted by data from the 
lES study (Coombes et al., 2004a), in which patients were randomised to continued 
treatment with either the aromatase inhibitor Exemestane or tamoxifen following 
completion of 2-3 years of tamoxifen. This trial also showed a benefit in disease free 
survival in those patients switched to Exemestane. This benefit was shown equally in 
both PR negative and PR positive patients. We hypothesised that in this scenario 
many patients with de novo tamoxifen resistance would in effect be excluded from 
this trial as many recurrences would have occurred prior to randomisation. Perhaps 
most interestingly then, our results also show that HER and PR status do not appear to 
influence relapse on tamoxifen after 3 years of tamoxifen treatment which parallels 
these recently published lES results (Coombes et al., 2004a).
We showed no significant differences in relapse rates on tamoxifen relative to PR 
status in ER positive patients who had already suiwived disease free for three years.
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These results support our conclusion that PR negativity identifies a group of tumours 
with de novo tamoxifen resistance, who may therefore respond to aromatase inhibitors 
if treated early, i.e. from time of diagnosis (as per the ATAC trial). We suspect these 
patients are in effect excluded from the lES study by virtue of their having relapsed 
prior to the randomisation point of this study. This suggests that PR status is a time 
dependent predictor of early relapse due to de novo tamoxifen resistance. Further 
evidence for this supposition is provided for the moderate association between PR 
status and outcome in the ARNO 95/ ABCSG 8 Trials (Jakesz et al., 2004) which 
randomised patients to either tamoxifen or Anastrasole following only 2 years of 
tamoxifen treatment. Taken together, these data stiongly support the conclusion that 
the predictive value of PR, and possibly HERl-3, expression is time dependent and 
hence identifies patients at high risk of de novo tamoxifen resistance. However, data 
from the BIGl-98 study, which is comparable to ATAC in design, does not appear to 
support this argument (Jakesz et a l, 2004). Whilst the most likely explanation of this 
is under-powering of the sub-analysis relating to PR status, caution should be 
exercised before extrapolating results from ATAC and those presented here to 
treatment of patients. These results also highlight the importance of distinguishing 
clearly between the molecular pathways involved in de novo and acquired resistance, 
particularly in the clinical setting in terms investigating any changing molecular 
profile of recurrent tumours. Ultimately investigation of the underlying mechanisms 
behind later recurrences may demonstrate up-regulation of previously dormant HERl- 
3 pathways or alternatively it may involve other, as yet unknown pathways, which 
may also be detectable at diagnosis.
From a clinical perspective, data from the ATAC trial, if confirmed, may provide 
sufficient support to encourage early switching of ER positive patients from
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tamoxifen to aromatase inhibitors if their tumours do not express PR. Despite the 
importance of these findings however, additional information from prospective 
clinical trials is required before recommendations relating to patient management can 
be made. In this context it is particularly important that translational science tumour 
banks are being collected in the context of current clinical trials. The value of such 
tumour banks is clearly demonstrated by the AT AC data, despite the retrospective 
nature of the analysis. The data presented here supports extending pre-planned 
prospective analysis, such as that defined within the multinational TEAM trial 
(prospectively testing for interactions between HERl-3 and outcome relating to 
tamoxifen or Exemestane treatment), to incorporate measurement and reporting of PR 
status. Such analyses should, in the light of ongoing variations in PR and ER 
measurement (Chebil et a l, 2003), be performed centrally. The recent redesign of the 
TEAM trial to allow comparison of “switching” from Tamoxifen to Exemestane after 
2-3 years directly with continuous Exemestane treatment provides an ideal platform 
for this hypothesis to be tested. The ability to select, at diagnosis, patients at high risk 
of early relapse on tamoxifen could provide the opportunity to tailor their adjuvant 
therapy differently, either in terms of an aromatase inhibitor or by supplying them 
with a HER family inhibitor such as Iressa or Herceptin to be used in conjunction 
with their endocrine treatment (particularly if they are pre-menopausal and hence not 
suitable for aromatase inhibitors).
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4.4 HERl-3 activates membrane ER via 
phosphorylation. A role for phosphoryiated ERa in 
tamoxifen resistance?
Having provided evidence that HERl-3 overexpression is associated with de novo 
tamoxifen resistance, attention must be focussed on the mechanisms and pathways 
involved. Several mechanisms have been proposed by which the type I RTKs may 
modify response to oestrogens and tamoxifen. As discussed previously there is a 
considerable body of biological evidence suggesting that cross talk between the HER 
family signalling pathways and the ER at several levels may be responsible. 
Signalling pathways activated by the type I RTKs have been shown to activate the ER 
by phosphoiylation at sites including those on the API region of the ER. As discussed 
previously, the serine phosphorylation site SI 18 on the API region of ER is a target 
for phosphoiylation by MAPK (Kato et al., 1995). MAPK is a component of the Ras- 
Raf-MAPKs pathway and over-expression or activation of this pathway has been 
associated with a poor clinical response to tamoxifen therapy (Gee et al., 2001) and to 
tamoxifen resistance in vitro (Benz et a l, 1993; Kurokawa et a l, 2000). In addition 
the phosatidylinositol-3 kinase (PI-3K) - Akt pathway has been also shown to mediate 
activation of the ER at serine 167 (also in the API region) (Campbell et a l, 2001) 
resulting in reduced sensitivity to tamoxifen in vitro. The consequence of 
phosphorylation of the ER in breast cancers may be to promote the known receptor 
agonistic activity of tamoxifen and to enhance transcription of genes involved in 
proliferation and genes which block apoptosis leading to tumour growth. Therefore 
our initial hypothesis was that we would be able to demonstrate a relationship 
between overexpression of the type I RTKS at the membrane and phosphoryiated ER
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at the nucleus, and that these patients would also be more likely to relapse on 
tamoxifen therapy.
Our results demonstrated the presence of phosphoryiated ERa within the nuclear, 
cytoplasmic and membrane components of breast cancer cells. In terms of the nuclear 
staining we demonstrated results that initially may be thought to be out of keeping 
with our original hypothesis. We demonstrated no correlation between HERl-3 and 
phosphoryiated nuclear ERa (serl67) and nuclear expression of pERaSerl67 was 
associated with smaller tumour size and lower grade, hi addition, HERl-3 was 
inversely related to expression of pERa at the Seri 18 site. In fact, these results are in 
keeping with other recently published results using the same pERal 18 antibody. 
Murphy et al determined pERal 18 staining in 117 primary breast tumours from node­
negative patients who were subsequently treated with adjuvant tamoxifen. They also 
demonstrated a positive correlation of nuclear pERal 18 with expression of total ERa, 
PR positivity, lower grade and longer disease free survival (Murphy et al., 2004a; 
Murphy et al., 2004b). In addition. Gee et al have published preliminary results using 
this antibody (cohort size not described) which also demonstrated associations with 
improved disease free survival and PR status. (Gee et al., 2005). These studies, when 
combined with data presented here, would suggest that the effects of HERl-3 in 
promoting tamoxifen resistance may be mediated through mechanisms other than 
direct phosphoiylation of the ER, at these specific sites, within the nucleus of breast 
cancer cells and that phosphoryiated nuclear ER acts as a marker of an intact, 
functional, ERa signalling pathway. However these results are also complicated by 
the fact that Murphy et al reported an association between nuclear pERal 18 staining 
and MAPK overexpression mid Gee et al noted a direct association with Akt activity 
which has also been demonstrated by ourselves (Kirkegaard et ah, 2005). The
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possibility that ER function may be modified by either phosphoiylation at other sites, 
or via phosphoiylation of co-factors, cannot be cuirently excluded.
In addition to the widespread nuclear phosphoiylated ER staining, we also found that 
a small but significant subset of patients demonstrated either pE R allS  or pE.Ral67 
staining at the membrane. Whilst the Murphy group did not comment on the presence 
of membrane staining (Murphy et al., 2004a), Gee et al commented on its presence 
but failed to link it with any meaningful clinical relationships (Gee et al., 2005). In 
contrast to our results found with nuclear staining we have also demonstrated novel 
findings associating phosphoryiated ERa at the membrane with HERl-3 
overexpression and increased tumour size, which may indicate a different function for 
the ERa at this site.
In the late 1970s Pietras & Szego (Pietras and Szego, 1977) reported the presence of 
high affinity binding sites for oestrogen associated with the plasma membranes of the 
MCF7 human breast cell line. This observation was largely ignored until recently, 
when evidence for non-genomic actions of ERa increased, particularly as a postulated 
explanation for the more rapid signalling via signal transduction pathways normally 
activated by growth factor receptors, produced by oestrogen stimulation (Simoncini et 
al., 2000; Kousteni et al., 2001; Castoria et al., 1999). This non genomic signalling 
appears to take place outside the nucleus and now it appears that oestrogens are able 
to mediate some of these actions through a membrane associated oestrogen receptor 
(Watson and Gametchu, 1999; Simoncini et a l, 2000; Pappas et a l, 1995).
Recent work has suggested that these membrane receptors may be particularly 
important in the role oestrogen plays in ‘su m v a l or anti-apoptotic mechanisms 
(Marquez and Pietras, 2001; Razandi et a l, 2000). Oestrogenic stimulation of
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membrane ERa has been shown to result in rapid stimulation of G proteins, protein 
kinase C, protein kinase A, MAPK and PI3K activation in vitro (Migliaccio et a l, 
1996; Simoncini et a l, 2000; Zivadinovic and Watson, 2005; Razandi et a l, 2003b; 
Filardo et a l, 2002; Kelly et a l, 1999). These kinase signals have been shown to 
activate nuclear ERa transcriptional activity (Sun et a l, 2001a). Therefore the 
genomic and non genomic actions of ERa seem to be complementary and may even 
synergise via cross-regulatory interactions mediated by cross talk with growth factor 
pathways (Pedram et a l, 2002). The physiological relevance of rapid extranuclear 
signalling has been provided by experiments showing that these actions contribute to 
the anti-apoptotic effect of oestrogen in bone (Kousteni et a l, 2002) and to the rapid 
effects of oestrogen on vasodilation and protection of endothelial cells against injury 
(Figtree et a l, 2003). Whilst in vitro evidence for this association between 
membranous ERa and the HER family and its downstream pathways has been shown 
in an increasing number of cell types, our results demonstrate for the first time a 
potential link between the 2 pathways in human breast cancer specimens.
In addition to this we also show a correlation between membranous phosphoiylated 
ERa and disease relapse on tamoxifen at Seri 18 but not at Seri 67. There is some 
evidence that, in contrast to genomic activity (i.e. action of the ERa to promote gene 
transcription), non-genomic ERa activity can be stimulated by SERMS such as 
tamoxifen (Zivadinovic and Watson, 2005; Aronica et a l, 1994; Cato et a l, 2002). 
Therefore tamoxifen may be incapable of breaking (or even may stimulate) any cycle 
linking non-genomic and genomic ERa the growth factor pathways. Thus membrane 
bound ERa (in conjunction with the HER family) may be responsible for initiating 
tumour cell proliferation even in the presence of tamoxifen resulting in de novo 
tamoxifen resistance. Aromatase inhibitors however, act by depriving the
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environment of oestrogen which would shut o tf both the nuclear and membranous ER 
activity resulting in termination of this cycling.
It is not clear from our results if the interaction demonstrated between phosphoryiated 
ERa at the membrane and HERl-3 is true for pERa only or whether it represents an 
interaction with membranous ERa in general, regardless of phosphoiylation status. 
Membranous ER staining has not traditionally been detected in routine diagnostic 
ERa immunohistochemistiy staining and indeed none was seen in our study. This may 
reflect an antibody concentration effect whereby the much smaller numbers of ERa 
receptors at the membrane are overshadowed by the greater intensity of ERa nuclear 
staining. By detecting phosphoryiated ERa only, this concentration effect may 
become less prominent, enabling detection of staining of pERa at the membrane.
These findings emphasise the importance of determining the non-classical actions of 
ERa particularly with respect to interactions with cell survival pathways. However 
further work is needed to confirm any correlation that HERl-3 associated 
membranous ERa may have with tamoxifen resistance. These results also have 
implications for establishing ERa status, particularly in the clinical diagnostic setting. 
Whilst, over the years, ERa detection has progressed from ligand binding assays to 
standardised IHC testing, more detailed analysis in terms of location and function of 
the receptor may become the norm for diagnostic testing in the future. As we become 
increasingly more aware of the complex nature of ERa and its interactions, these 
results only serve to highlight the difficulties involved in identifying the mechanisms 
behind tamoxifen resistance and subsequently in developing treatment strategies to 
overcome them.
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4.5 HER4
We have demonstrated for the first time that the H4.77.16 antibody can be used 
successfully in formalin fixed tissue. In keeping with previous reports we also have 
found membranous, cytoplasmic and nuclear staining. The HFR-1 antibody is raised 
against an intracellular epitope aal 249-1264 (therefore will detect both the intact and 
cleaved form of 4ICD) whilst the H4.77.16 antibody is raised against an extracellular 
fragment (hence will detect only the full length HER4 protein or the cleaved 
extracellular domain at the cell surface). This difference in antigen site may explain 
the different staining patterns we have seen in terms of location; with each antibody 
appearing to select for distinct compartments. Thus HFRl may select for cytoplasmic 
and nuclear HER4 ICD whilst H4.77.16 selects for membranous HER4 and possibly 
also HER4 being recycled in cytoplasm or nucleus. This ability to distinguish between 
site and function of HER4 and its fragments is particularly important with recent 
evidence highlighting the different functions of nuclear and mitochondrial HER4. We 
now know that whilst HER4 at the membrane is accountable for signal transduction, 
mitochondrial 4ICD nuclear HER4 appeal's to be involved in apoptosis mediation 
(Vidal et a l, 2005) and nuclear HER4 is required for mammary gland development 
and lactation.
Despite the differences seen in staining location, we demonstrate that in terms of 
relationships with pathological variables, HER family members and prognostic 
importance, when tested under standardised conditions on the same set of tumours; 
both antibodies provide generally similar results. The exception to this is the 
association that H4.77.26 detected nuclear HER4 has with poorer survival. This
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correlates with recently published results demonstrating that whilst membranous 
HER4 was associated with a good prognostic outlook, nuclear HER4 was associated 
with significantly shorter sum val times (Junttila et al., 2005). Interestingly though 
this study was using the HFRl antibody. Clearly this demonstrates that despite strong 
evidence for the role of the cleaved 4ICD, intact HER4 may also have a significant 
role to play.
We have not demonstrated any association between membranous HER4 and survival 
when considered alongside other HER family members or alone. However we did 
demonstrate an association between membranous and cytoplasmic HER4 and known 
poor prognostic variables. These results have not helped clarify the ongoing debate on 
the role of HER4 in breast cancer but may be explained by several factors. Our 
patients are a tamoxifen treated group, the majority of which are ER positive. 
Previous studies, including ours, have suggested a greater tendency for HER4 to be 
associated with ER positive tumours (Tang et al., 1999; Wright et a l, 1992; 
Pawlowski et a l, 2000). Within this generally less aggressive set of cancers, the effect 
of HER4 may be less pronounced.
The patterns of coexpression reported between HER4 and other family members may 
also explain some of the conflicting reports here and in published studies. In contrast 
to this study, in our previously reported series where HER4 was associated with good 
prognosis, we found minimal overlap between HER4 positive patients and other HER 
family members (Witton et a l, 2003). In addition a recent large study has suggested 
that the “protective” effect of HER4 may be abrogated if expression of other members 
of the type I RTKs are also present (Abd El-Rehim et al, 2004). That may explain 
why on this occasion, where we demonstrate higher levels of co-expression, we no 
longer see the beneficial results on survival reported previously.
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This is also consistent with data from cell lines showing that whilst HER4 can induce 
growth aiTest and differentiation (Sartor et a l, 2001; Williams et a l, 2003), when co­
expressed with other receptors, such as HER2 & HER3, signalling through these 
receptors promotes proliferation and ovemdes the effects seen when HER4 is 
expressed in isolation (Yarden, 2001b).
In conclusion, we have demonstrated that antibodies against 2 different HER4 
receptor antigen sites identify clear differences in staining patterns. The differences in 
published reports may well reflect the differing abilities of antibodies to detect 
distinctly different HER4 functions. In the future careful attention to the location and 
consequent function of the HER4 fragment targeted is needed. It is possible that 
antibodies more specifically targeting the TACE or BH3 domain may prove valuable 
in further elucidating the functions of HER4 particularly in regard to impact on 
clinical outcome in breast cancer.
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Chapter 5 Conclusion
The research presented here is particularly important because it demonstrates a time 
dependent element to tamoxifen resistance which is likely to reflect de novo 
resistance. Both HERl-3 and PR expression, in ER positive primary breast cancers, 
could now be used to identify patients who may exhibit de novo tamoxifen resistance. 
Furthermore both PR and FIERI-3 appear to be time dependent predictors of risk of 
relapse with risk declining markedly after 3 years of tamoxifen treatment. These data, 
taken in context with data from the recent AT AC and lES studies, strongly support 
the hypothesis that HERl-3 and PR status identifies separate tamoxifen resistant 
tumour subsets, and that patients with HERl-3 expression or lacking PR expression 
are likely to benefit from early implementation of therapy with aromatase inhibitors. 
Conversely, these data would also suggest that ER/PR positive tumours lacking 
FIERI-3 expression (over 50% of cases), could be treated by switching to an 
aromatase inhibitor following 2-3 years of tamoxifen treatment. Further research to 
determine the mechanisms relating to tamoxifen resistance and to test this hypothesis 
in the context of the redesigned TEAM trial will provide a valuable insight into the 
most appropriate future therapeutic options for differing sets of breast cancer patients. 
In addition to reinforcing the concept that members of the HER family are involved in 
tamoxifen resistance, we have also produced novel evidence with regard to how this 
may be taking place. Phosphoryiated ER at the nucleus was not linked with the FIER 
family or with tamoxifen resistance and instead appears to indicate a functional 
responsive ER. Detection of the presence of phosphoiylated ER at the nucleus may in 
fact be more relevant if tested for after the commencement of tamoxifen therapy, with 
those still expressing it at that time being possible candidates for developing clinical 
tamoxifen resistance. Detecting the presence/absence of this marker during
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neoadjuvant endocrine trials may shed more light on this in the future. With regard to 
the membranous phosphoiylated ERa staining we have demonstrated relationships 
with both the HER family and with resistance to tamoxifen. This comes at a time 
when much attention has been focussed on membranous ERa signalling mechanisms 
and our results should contribute to this debate as it is the first time this relationship 
has been demonstrated in human breast cancer specimens. Further work is required to 
more closely examine the nature of this link between ERa at the membrane and the 
HER family. Particularly interesting are the Src family kinases which are known to be 
involved in cancer cell adhesion and migration. There is evidence suggesting that 
specific G proteins mediate the ability of oestrogen receptors at the membrane to 
activate matrix metalloproteinases via Src to lead to transactivation of EGFR. 
Analysis of expression of Src within our database has been planned.
While clinical knowledge with regard to the mechanisms behind de novo resistance is 
rapidly progressing, further attention should be directed towards identifying the 
causes of acquired resistance. This would include for example the scenario of 
PRpos/HERneg patients who initially do well on tamoxifen but who develop 
resistance at a later date. Do these patients develop secondaiy stimulation of the HER 
pathways, or do they have an unidentified marker that could have been identified at 
the outset? Whilst it appears that fewer ER positive patients have de novo resistance 
to aromatase inhibitors, will these agents also be linked to a later acquired resistance 
pattern as demonstrated in in vitro with regard to long term oestrogen deprivation 
(Chan et al., 2002)7 Traditionally it has been difficult to obtain histological tissue 
from breast cancer recurrences (many metastasis occur in bone for example which is 
difficult to biopsy). However information gained from these samples may be 
invaluable with regard to determining causes of acquired resistance. A recent study
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using detecting serum HER2 showed that 25% of patients treated with tamoxifen and 
26% of patients treated with letrozole in a metastatic or advanced disease setting 
converted from serum HER2 negative to HER2 positive at the time of progression 
(Lipton et al., 2005). This switch in HER status has also has been detected in formalin 
fixed tissue (Gutierrez et af, 2005) (in very small numbers).
Further research into causes of tamoxifen resistance (both de novo and acquired) is 
particularly important for younger women with breast cancer. Whilst postmenopausal 
HER positive women have the advantage of being able to switch to aromatase 
inhibitors, premenopausal women may not. If the aetiology behind tamoxifen 
resistance in these younger women is clearly identified as being due to HERl-3 
overexpression, then targeted therapy such as Herceptin or Iressa can be used. Many 
clinical trials using combinations of either aromatase inhibitors or tamoxifen with a 
tyrosine kinase inhibitors have begun in the metastatic setting and may soon be 
extended to the adjuvant treatment (Johnston, 2005). There are also other emerging 
dual-inhibitor therapies (Reid et al., 2007) such as Lapatinib, a tyrosine kinase 
inhibitor of both EGFR and HER2, which has shown clinical benefit in trastuzumab 
refractory metastatic breast cancer.
Breast cancer suiwival rates have improved markedly over the years largely because 
of better directed therapies based on clinical trial evidence. However continued 
improvements are likely when treatment can be initiated on individual, rather than 
population based, characteristics. The recent HERA trial results are evidence of 
targeted individual treatment based on a single biological marker. Identification of 
further markers will be able to help clinicians give detailed prognostic and treatment 
advice tailored to the individual cancer patient.
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Appendix II
Photomicrographs of immunohistochemical TMA staining
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